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Summary 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide. Implementation of interdisciplinary and aggressive treatment regimens 
have only marginally improved the clinical outcome of patients with advanced 
HNSCC, which is mainly due to the invasive growth pattern and high rate of 
therapeutic resistance as a main cause for tumor relapse. Accordingly, unraveling 
underlying molecular mechanisms and relevant candidate genes as potential drug 
targets for more efficient and less toxic treatment is eagerly awaited. 
In the past, induced expression of the mouse homologue of submaxillary gland 
androgen regulated protein 3A (SMR3A), a family member of the opiorphin gene 
family, was identified in a mouse xenograft model of tumor relapse in oral 
carcinogenesis. More recently, high SMR3A expression was confirmed in a 
substantial amount of patients with primary oropharyngeal squamous cell carcinoma 
(OPSCC) and served as an independent risk factor for an unfavorable survival. 
However, the regulation of SMR3A in treatment resistant tumor cells and its potential 
role in tumor relevant processes remained elusive and is the major objective of this 
PhD thesis. 
First, a cell culture model with ectopic overexpression was established in a HNSCC 
cell line but did not support a causal link between SMR3A and tumor cell 
proliferation, migration or adhesion under normal growth conditions. These findings 
raised the attractive question, whether up-regulation of SMR3A represents a 
surrogate marker for signaling cascades implicated in treatment resistant of tumor 
cells. To address this question, several HNSCC cell lines with low basal SMR3A 
expression were treated with a protocol of fractionated irradiation. Elevated SMR3A 
expression was a common feature for surviving tumor cells and was accompanied by 
induced expression of the estrogen receptor 2 (ESR2), suggesting a regulation by 
activated ESR2 signaling. Indeed, SMR3A could be induced in HNSCC cell lines by 
estradiol in a time and dose-dependent manner, and estradiol-induced expression 
was alleviated by co-treatment with either 4-Hydroxytamoxifen or Fulvestrant, two 
well established inhibitors of ESR2 signaling. The clinical relevance was further 
validated by a positive staining for ESR2 in tumor cells of primary OPSCC and 
induced apoptosis of tumor cells after combined treatment with Fulvestrant and 
fractionated irradiation in vitro. 
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In summary, the presented data strongly support a model in which accelerated 
SMR3A expression indicates active ESR2 signaling as a key mechanism for survival 
and clonal evolution of radioresistant tumor cells. As a consequence, HNSCC 
patients with co-expression of SMR3A and ESR2 in tumor cells prior or during 
radiotherapy are at high risk for treatment failure, but might benefit from adjuvant 
therapy with 4-Hydroxytamoxifen or Fulvestrant. However, additional studies in pre-
clinical models are needed as a proof of concept and to pave the way to clinical trials 
in the future. 
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Zusammenfassung 
Plattenepithelkarzinome der Kopf-Hals-Region (HNSCC) sind die am sechst-
häufigsten auftretenden Krebsarten weltweit. Die Anwendung von multidisziplinären 
und aggressiven Behandlungsoptionen führte nur zu einer geringen Verbesserung 
für Patienten mit Kopf-Hals Tumoren in fortgeschrittenen Stadien. Die Gründe für die 
geringe Verbesserung sind einerseits das hochinvasive Potential der Tumore und 
andererseits ein hoher Grad an Therapieversagen welche zu erneutem 
Tumorauftreten beitragen. In Folge dessen, ist es von großer Bedeutung, die zu 
Grunde liegenden molekularen Mechanismen aufzuklären und Gene als Ansatzpunkt 
für neue Medikamente zu erforschen, die eine effektivere und weniger toxische 
Behandlung ermöglichen.  
Kürzlich wurde die Überexpression von „submaxillary gland androgen regulated 
protein 3A“ (SMR3A), welches der Opiorphin-Gen-Familie angehört, in einem 
operativen Rezidiv-Mausmodel entdeckt. Die Überexpression wurde in 
vorhergegangenen Studien  in einer spezifischen Gruppe von Patienten mit Tumoren 
des Oropharynx identifiziert und diente als unabhängiger prognostischer Marker für 
den Nachweis einer schlechten Überlebensrate.  Jedoch gab es bisher keine 
Erkenntnisse über die Regulation von SMR3A in behandlungsresistenten 
Tumorzellen sowie  dessen potentielle Rolle in Tumor-relevanten Prozessen. Dies 
herauszufinden ist Hauptziel dieser Dissertation. 
Dazu wurde zuerst ein Zellkultur Model einer HNSCC Zelllinie etabliert, welches eine 
ektopische Überexpression aufwies. Dieses zeigte unter normalen 
Wachstumsbedingungen keinen kausalen Zusammenhang zwischen einer hohen 
Expression von SMR3A und verändertem Tumorzellverhalten bzgl. deren 
Proliferation, Migration sowie Adhäsion. Aus diesem Grund wurde untersucht, ob die 
Überexpression von SMR3A als Surrogatmarker für Signalkaskaden, welche im 
Therapieversagen involviert sind, dienen kann. Dazu wurden mehrere HNSCC 
Zellinien, die eine geringe basale SMR3A Expression aufwiesen, fraktioniert 
bestrahlt. Die überlebenden Zellen zeigten stets eine gesteigerte SMR3A 
Expression. Diese ging mit einer ebenso gesteigerten Expression des Östrogen 
Rezeptor betas (ESR2) einher, welche einen Zusammenhang zwischen beiden 
Proteinen vermuten lies. Tatsächlich konnte SMR3A zeit- und dosisabhängig in 
HNSCC Zelllinien über Estradiol induziert werden. Die beiden ESR2-Antagonisten 4-
Hydroxytamoxifen sowie Fulvestrant, konnten diese Estradiol-abhängige Induktion 
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effizient blockieren. Die klinische Relevanz konnte zudem durch eine positive ESR2-
Färbung in Tumoren des Oropharynx gezeigt werden sowie durch verstärkte 
Apoptose in Tumorzellen in vitro nach einer kombinierten Therapie aus fraktionierter 
Bestrahlung und Fulvestrant. 
Zusammenfassend weisen die Daten auf ein Model hin, in welchem erhöhte SMR3A 
Level als Marker für einen aktiven ESR2 Signalweg dienen. Dieser aktive ESR2-
Signalweg ist ein Schlüsselmechanismus für ein klonales Auswachsen 
radioresistenter Tumorzellen. Als Konsequenz haben Patienten mit einer hohen Co-
Expression beider Proteine vor und während der Therapie, ein hohes Risiko für 
Therapieversagen auf Grund der Entstehung radioresistenter Zellen. Gegebenenfalls 
profitieren diese Patienten von einer kombinierten adjuvanten Therapie aus 4-
Hydroxytamoxifen oder Fulvestrant im Zusammenhang mit Bestrahlung. Jedoch sind 
in der Zukunft weitere Studien in pre-klinischen Modellen von Nöten um den Weg für 
klinische Studien zu ebnen.  
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1.1 Head and neck squamous cell carcinoma (HNSCC) 
1.1.1 Epidemiology and risk factors of HNSCC  
Human malignancies of the head and neck region are according to the World Health 
Organization (WHO) the sixth most common cancer worldwide. Annually, 
approximately 50,000 new cases are affected by this tumor entity in the United 
States with nearly 10,000 disease related death cases per year. The 5-year survival 
rate is approximately 40-50% depending on many individual factors such as e.g. the 
tumor size at time point of diagnosis. The majority of patients are male at an average 
age of 65 years at time of diagnosis (1-6). The highest incidence rate for head and 
neck cancer occurs in the industrialized countries with approximately two third of all 
cases worldwide (7).  
 
95% of cancers at the head and neck region arise from the squamous mucosa of the 
upper aerodigestive tract and are termed head and neck squamous cell carcinomas 
(HNSCCs). Major locations of origin for HNSCC are depicted in Figure 1. Those 
encase the oral cavity including the tongue, the hard plate and the floor of the mouth, 
the nasopharynx, oropharynx and hypopharynx, the larynx as well as the nasal 
cavity. In North America and in Europe cancers of the oral cavity and the oropharynx 
represent the most common cases. In pacific countries, mainly nasopharyngeal 
tumors arise (2,4,8,9). 
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Figure 1: Major loci for the development of head and neck squamous cell carcinomas (HNSCC). 
The majority of head and neck squamous cell carcinomas arise in the oral cavity including the tongue, 
the larynx, the nasopharynx, hypopharynx and oropharynx as well as within the nasal cavity. 
http://www.cancer.gov/PublishedContent/Images/images/cancer-types/head-neck/headandneck-diagram.jpg 
 
Risk factors for the development of HNSCC can be divided into traditional as well as 
more recently established risk factors. Traditional risk factors are alcohol as well as 
tobacco consumption, which were shown to have a multiplicative effect. Tobacco 
consumption includes cigarette smoking but also chewing tobacco with or without 
betal nuts, which is the main risk factor in South Asian countries and causes one of 
the highest incidence rates worldwide (4,8,10,11,12).  
 
More recently established risk factors include infection with high-risk virus types such 
as Epstein-Barr Viruses (EBV) or Human Papilloma Viruses (HPV) (4,11,13). The 
Epstein-Barr virus is a human pathogenic, double strand DNA virus of the herpes 
family. An infection of patients with EBV is associated with undifferentiated 
nasopharyngeal tumors (14). 
Human Papilloma Viruses (HPV) are DNA viruses from the papillomavirus family and 
an infection with predominantly HPV-16 is associated with oropharyngeal squamous 
cell carcinomas (OPSCCs). Numerous studies have compared the clinical profile of 
HPV-positive vs. HPV-negative HNSCC tumors. HPV-positive tumors are associated 
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with a lower age of disease onset as well as a favorable prognosis concerning clinical 
outcome. Furthermore, HPV-positive tumors are associated with oropharyngeal 
tumors whereas HPV-negative tumors are not associated with any predilection site. 
Moreover, an escalating incidence of HPV-positive OPSCCs have been described, 
while HPV-negative HNSCCs, associated with traditional risk factors, show a 
decrease in cases over the last decade mainly due to smoking prevention programs 
(4,15-19).  
 
1.1.2 The mutational landscape of HNSCC development 
The development of HNSCC is a multistep process, which requires multiple 
aberrations within the mucosal tissue consisting of a high number of genetic and 
epigenetic alterations (2,17,20). 
 
The first step in the pathogenesis of HNSCC is the benign squamous hyperplasia, 
which develops into a dysplastic lesion. The dysplasia, the earliest manifestation of a 
pre-cancerous lesion, is characterized by abnormal growth as well as differentiation 
of the epithelial layer. From a genetic point of view, loss-of-heterozygosity (LOH) 
occurs leading to genetic instability mainly affecting p16 inactivation as well as p53 
mutation (21,22). P53 is the major tumor suppressor gene. Its mutation is a hallmark of 
cancer occurring to a high extent in HNSCC as well as in a great variety of other 
tumor entities where it can become inactivated via genetic mutation or gene promoter 
hypermethylation (1,17,23,24).  
In HPV positive HNSCCs, the oncogene transcript E6 leads to the inactivation of p53 
as one of the first steps in neoplastic transformation of HPV infected cells (1,17,25-27). 
 
Finally, a carcinoma in situ progresses to a carcinoma, which is characterized by a 
break through the epithelial basement membrane allowing tumor cells to invade into 
the stromal compartment. Also within the later two steps, genetic alterations occur 
leading to uncontrolled cell cycle progression (17) (Fig. 2). 
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Figure 2: Molecular mechanism of HNSCC development. 
Head and neck cancer progression is a multistep process, which develops from a benign squamous 
hyperplasia till the full development of a carcinoma. Each step is connected with a change in 
morphology of the epithelial cells and the basement layer as well as with a change in genetic 
alterations of important genes involved in tumor cell behavior as well as cell cycle control. 
(Picture was taken from Pai et al, 2009) 
 
1.1.3 Therapy and clinical outcome  
HNSCC represents a rather heterogeneous tumor entity with regard to biological as 
well as clinical features. This fact makes appropriate treatment decision extremely 
difficult (2,4). 
Surgery or definitive radiotherapy is the primary treatment option for HNSCC patients 
with early-stage tumors. These patients have a good prognosis with survival rates of 
60% to 80% (3,17,28,29). Advanced HNSCC patients are treated using a 
multidisciplinary approach. The major goal of the surgical intervention in patients with 
advanced HNSCC is the reduction of the primary tumor bulk to give rise to second 
line treatment modalities including radiotherapy as well as chemotherapy using e.g. 
cisplatin (4,11,30).  
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During the last decades, targeted therapies were established for the treatment of 
HNSCC. For example Cetuximab, a monoclonal antibody against the epidermal 
growth factor receptor (EGFR), has been approved for the treatment of advanced 
HNSCC or in case of tumor relapse in combination with radiotherapy. The treatment 
was shown to lead to enhanced locoregional control as well as to a benefit in overall 
survival without impaired quality of life (17,24,31,32).  
The overexpression of EGFR can be detected in a great number of HNSCC patients, 
which can be treated using Cetuximab (31,33-37). Nowadays, it is known that only a 
small subset of patients benefit from the treatment because the majority develops 
resistance due to intrinsic as well as acquired mechanism over time (38,39). 
 
During treatment, many patients suffer from severe side effects leading to loss of life 
quality. The major side effects include pain, problems at speaking and swallowing or 
eating, vomiting as well as long time periods in hospitals. Most side effects are due to 
the high toxicity of the applied treatment mainly at chemotherapy as well as 
treatment-related side effects due to surgical intervention (40,41). 
 
One major challenge in the field of HNSCC is the early identification of patients and 
therefore early treatment leading to good prognosis concerning clinical outcome. In 
order to achieve this, the search for new diagnostic biomarkers is required. A 
biomarker needs to be defined as a marker gene, which is absent under 
physiological conditions and becomes highly upregulated under pathogenic 
conditions or vice versa (3,17).  
Furthermore, therapeutic markers are also needed to identify a subset of patients 
with defined gene pattern, which can become treated in a specific manner leading to 
less toxic side effects as well as a more specific therapy (17).  
 
1.1.4 The concept of field cancerization 
The high rate of treatment failure leading to local relapses as well as of recurrent 
tumors during disease progression severely decreases overall- as well as 
progression-free survival rates of patients (42,43). This problem was declared as the 
concept of “field cancerization” or “field change cancerization” and is depicted in 
Figure 3 (4,44).  
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During primary surgical treatment, the tumor bulk is removed as indicated via the 
surgical resection site. The margin of tumor resection is analyzed for remaining tumor 
cells. Tumor cells can invade into the healthy tissue and become quiescent and 
might also escape treatment by radio- and/or chemotherapy due to their slow-cycling 
capacity. Both adjuvant treatment options target preferentially fast-cycling cells, 
which is a normal characteristic of tumor cells. Therefore, quiescent cells can escape 
and survive primary as well as adjuvant treatment, giving rise to a recurrent tumor 
(4,17).  
 
 
Figure 3: Concept of field cancerization. 
During cancer progression, a primary tumor bulk is formed, which can be removed via surgery. Tumor 
cells invading into the healthy surrounding tissue are not removed via surgery and can become 
quiescent during cancer progression. Quiescent cells are not of target of second-line treatment 
modalities such as radiation and / or chemotherapy due to their slow-cycling characteristics. These 
quiescent cells can become reactivated after some time and form a recurrent tumor. 
(Picture was taken and modified from Leemans et al, 2010) 
 
 
 
 
Tumor bulk 
surgical resection site 
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1.2 Submaxillary gland androgen regulated protein 3A (SMR3A) 
1.2.1 The identification of Smr1 in an orthopic floor-of-the-mouth mouse tumor 
model 
In 2010, Behren and coworkers published an orthopic floor-of-the-mouth mouse 
tumor model to mimic tumor relapse after surgery and to unravel underlying 
molecular mechanisms of tumor recurrence (Fig. 4) (45). 
 
 
Figure 4: Mouse model for tumor relapse after surgery. 
SCC cells were injected into the floor-of-the-mouth of mice. A primary tumor was formed which was 
removed via surgery. In 60% of all cases, a tumor relapse occurred. The samples of the primary and 
matched recurrent tumor were analyzed by global gene expression profiling to identify differential 
expression of genes, which became up- or downregulated in the recurrent sample compared to the 
primary counterpart. 
(Picture was taken and modified from Acuna Sanhueza et al, 2012) 
 
Global gene expression profiling with total RNA of matched primary tumors and their 
recurrent counterparts unraveled Smr1, the murine homologue of human SMR3A, as 
one of the most prominent upregulated genes in recurrent tumors compared to the 
primary counterpart (Fig. 4). Furthermore, Prol1, a homologue of Smr1, was also 
upregulated, indicating a clinical relevance of the whole gene family in tumor relapse 
(46). 
SCC cell line 
 
 
 
 
60% 
Primary tumour 
Surgery 
Recurrent tumour 
Behren et al., 2010 Int J Oncol 
Primary Recurrence 
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1.2.2 The role of opiorphins in physiology and pathophysiology 
SMR3A belongs to the gene family of opiorphins consisting of three homologues 
SMR3A, SMR3B and PROL1 (47). All three opiorphins are proteolytically processed 
into pentapeptides, which become secreted. The two human opiorphin gene family 
members SMR3A and SMR3B are closely related and are processed into the same 
pentapeptide (48).  
Opiorphins are expressed in salivary glands and the pentapeptides are released into 
the saliva where they can be detected using HPLC detection methods (49). 
Furthermore, opiorphins are reported to act as putative inhibitors of enkephalin-
catabolizing ectoenzymes such as the endogenous transmembrane metallo-
endopeptidase NEP / CD10 and the aminopeptidase APN / CD13 (48,50).  
In male rats, the rat homologue of SMR3A, Vcsa1, is differentially expressed during 
lifetime. The peak of 100- to 200-fold increase compared to birth occurs after 
puberty. Furthermore, the expression in female rats is significantly lower compared to 
their male counterparts during whole life. If androgen is present in small levels within 
the circulation, Vcsa1 becomes transcribed indicating a direct connection of Vcas1 
levels and the presence of the male sex hormone androgen (48,51). Furthermore, it 
was also shown for other family members of the opiorphin gene family that androgen 
leads to the secretion of the pentapeptides into the circulation (49). 
Recent publications have elucidated a role of SMR3A in erectile dysfunction (47,48,52). 
Tong and coworkers have proven that SMR3A is downregulated in patients with 
erectile dysfunction. The same results were furthermore obtained using rats and the 
SMR3A homologue Vcsa1. Injection of the protein product in rats using intracorporal 
injection could restore erectile physiology (47,52).  
 
Furthermore, opiorphins are known to have analgesic effects in vitro as well in vivo. 
They inhibit the processing of harmful stimuli such as pain within the acute as well as 
the long-term phase (50). 
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1.2.3 The expression of SMR3A in HNSCC 
In a previous study, the expression of SMR3A in the context of clinical outcome of 
oropharyngeal squamous cell carcinoma (OPSCC) patients was investigated. The 
protein expression of SMR3A was assessed by immunohistochemistry in a cohort of 
primary oropharyngeal squamous cell carcinomas using tissue microarrays (TMAs). 
A heterogeneous staining pattern for SMR3A expression within the analyzed cohort 
was determined. The normal healthy mucosa showed only a weak expression 
whereas the tumors ranged from a low to a very high expression of SMR3A, which 
was detectable in approximately 30% of all investigated cases. As expected, specific 
staining for SMR3A was detected within the cytoplasm of the tumor cells (53). 
 
A high SMR3A staining pattern significantly correlated with an unfavorable prognosis 
considering progression-free as well as overall survival (53).  
 
 
1.3 Major aim of the study 
The main objective of this study is to characterize the regulation and function of 
SMR3A in tumor cells to better understand its role in the pathogenesis and the 
clinical outcome of HNSCC patients. Following questions should be addressed: 
 
1) Does SMR3A gain-of-function by ectopic overexpression in an HNSCC cell 
line affect tumor relevant processes? 
2) Is SMR3A expression altered as a consequence of established treatment 
modalities and what are the underlying mechanisms? 
3) Do key components of SMR3A regulation represent putative drug targets for 
novel therapeutic strategies for HNSCC patients? 
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2. Materials 
2.1 Consumables and Equipment 
Table 1: Consumables and equipment. 
Consumables and equipment Company 
-80°C Freezer Harris, Germany 
Autoclave ibs Technomara, Germany 
Cell culture flasks (T25 / T75) Greiner Bio One, Austria 
Cell culture hood Hera Safe Thermo Fisher Scientific, USA 
Cell culture petri dishes Greiner Bio One, Austria 
Cell culture well plates  Greiner Bio One, Austria 
Cell incubator Binder, Germany 
Cell scraper TPP, Switzerland 
Centrifuge Eppendorf, Germany 
CoolCell® SV2 Stem Cell Cryopreservation 
System 
Biocision, USA 
Cooling centrifuge Eppendorf, Germany 
Cover slips 18mm Knittel, Germany 
Cryo freezing containers Thermo Fisher Scientific, USA 
Cryo vials Steinbrenner, Germany 
DAB substrate Dako, Denmark 
DAKO PAP Pen Dako, Denmark 
Filtertips Biozym Scientific, Germany 
Fluorescence Microscope BX50F Olympus, Germany 
Fridge Liebherr, Germany 
Gel electrophoresis chamber Bio-Rad, Germany 
Glass ware Fisherbrand, Germany 
IBIDI cell culture migration inserts (35mm, 
high) 
ibidi, Germany 
Ice machine Scotsman, UK 
Image Quant™  LAS 500 Gel Imaging system GE Healthcare, Germany 
Keyence Microscope BZ-9000 Keyence, Germany 
Luna™  Automatic Cell Counter Logos Biosystems, USA 
Magnet stirrer / heating plate Sigma Aldrich, USA 
MicroAmp® 96-well optical adhesive film Applied Biosystems, USA 
MicroAmp® fast optical 96-well reaction plate Applied Biosystems, USA 
Microscope BX-59F Olympus, Germany 
Microwave Robert Bosch GmbH, Germany 
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Milli-Q®  water purification system Millipore, USA 
MJ Mini Mini PCR Gradient Cycler Bio-Rad, Germany 
NanoDrop™  Spectrophotometer PeqLab, Germany 
pH meter WTW, Germany 
Pipetboy acu Brand, Germany 
Pipette tips without filter Micro-Bio-Tec, Germany 
Pipettes Gilson-Abimed, Germany 
Platform shaker Polymax 1040 Heidolph, Germany 
Power supply Power Pac 300/3000 Bio-Rad, Germany 
Reaction tubes (1.5ml / 2ml) Eppendorf, Germany 
Safe-Lock reaction tubes Eppendorf, Germany 
SDS-PAGE chamber Bio-Rad, Germany 
Steam cooker Braun, Germany 
StepOnePlus™  Real-Time PCR System Applied Biosystems, USA 
Super Frost® Plus Slides  Menzel Gläser, Germany 
VectaMount™  aqueous mounting medium VectorLaboratories, USA 
Vortex „Reax 2000“ Heidolph, Germany 
Water bath GFL M&S Laborgeräte, Germany 
Western Blot PVDF membrane Millipore, USA 
Wet blotting transfer system Bio-Rad, Germany 
Whatman 3MM paper GE Healthcare, Germany 
X-ray system X-Rad 320 Precision X-Ray, USA 
 
2.2 Chemicals 
Table 2: Chemicals. 
Compund Company 
Acetic acid Merck, Germany 
Acetone Sigma-Aldrich, Germany 
Acrylamide / Bisacrylamide Roth, Germany 
Agarose, Ultra pure Lonza, USA 
Ammoniumperoxidsulfate (APS) Sigma-Aldrich, Germany 
Ampicilin Sigma-Aldrich, Germany 
BCA reagent Thermo Fisher Scientific, USA 
Boric acid Sigma-Aldrich, Germany 
Bovine serum albumine, fraction V PAA, Austria 
BrdU (5-bromo-2-deoxyuridine) BD Pharmingen, Germany 
Bromophenole blue AppliChem, Germany 
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CaCl2  Merck, Germany 
Crystal violet  Merck, Germany 
DMSO  Merck, Germany 
DTT Merck, Germany 
ECL solution AppliChem, Germany 
EDTA  AppliChem, Germany 
Eosin Roth, Germany 
Ethanol > 99% Roth, Germany 
Ethanolamine Merck, Germany 
Eukitt Kindler, Germany 
G418 Thermo Fisher Scientific, USA 
GelRed™  Nucleic Acid Gel Stain Biotium, Canada 
Gene Ruler™  1 kb DNA ladder Thermo Fisher Scientific, USA 
Glycerol Roth, Germany 
Glycine GEBRU Biotechnik, Germany 
H2O2   Merck, Germany 
Haematoxylin AppliChem, Germany 
Hoechst H33342 Biomol, Germany 
Isopropanol Roth, Germany 
KCl  Roth, Germany 
Methanol Merck, Germany 
MgCl2  Roth, Germany 
Milk powder, non-fat Roth, Germany 
Na2HPO4 x 2H20  Merck, Germany 
NaCl  Roth, Germany 
NaH2PO4 x H20  Merck, Germany 
Natrium- deoxylcholat AppliChem, Germany 
NP-40 Fluka Chemie, Germany 
Paraffin Vogel, Germany 
Phosphatase Inhibitor Cocktail Sigma-Aldrich, Germany 
Protease Inhibitor Cocktail Sigma-Aldrich, Germany 
Red Load Taq Master Jena Bioscience, Germany 
RiboLock RNase Inhibitor Thermo Scientific, Germany 
RNase-free water Jena Bioscience, Germany 
Sodiumdodecylsulfate (SDS) GERBU Biotechnik, Germany 
Tetramethylethylenediamine (TEMED) Roth, Germany 
Tris-Base Roth, Germany 
Tris-HCl Roth, Germany 
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Triton X-100 AppliChem, Germany 
Tween-20 GERBU Biotechnik, Germany 
Xylol VWR, Germany 
β – Mercaptoethanol AppliChem, Germany 
 
 
2.3 Buffers and Solutions 
10 x Citrate buffer (pH 6.0) 
29.4g Tri-Sodium Citrate-2-hydrate 
 
10 x PBS 
1.5M NaCl 
27mM KCl 
82mM Na2HPO4 x 2H2O 
17mM NaH2PO4 x H2O 
 
PBST 
0.05% Tween-20 in 1 x PBS 
 
10 x TBE 
1M Tris 
20mM EDTA 
1M Boric acid 
 
10 x Running buffer for Western Blot electrophoresis 
250mM Tris 
192mM Glycine 
1% SDS 
 
1 x Western Blot Transfer buffer 
25mM Glycine 
0.15% Ethanolamine 
25% Methanol 
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RIPA buffer 
50mM Tris-HCl pH 7.5 
1% NP-40 
0.5% Natrium-deoxycholat 
150mM NaCl 
0.1% SDS 
 
4 x Laemmli buffer 
200mM Tris-HCl pH 6.8 
8% SDS 
40% Glycerol 
400mM DTT 
0.4% Bromophenol blue 
 
Blocking buffer for Western Blotting: 
1 x PBST 
5% Skin milk 
or: 5% BSA 
 
8% SDS 
40% Glycerol 
20% β - Mercaptoethanol 
0.002% Bromophenole blue 
 
6 x DNA loading dye 
0.25% Bromophenole blue 
0.25% Xylene cyanol 
30% Glycerol in water 
 
X - buffer 
0.5% Triton X-100 in PBS 1x 
 
T - buffer 
1% BSA / 0.2% Tween-20 in PBS 1x 
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10 x TNT 
1M Tris-HCl 
1.5M NaCl 
0.05% Tween-20 
 
TNT blocking buffer 
1 x TNT without 0.05% Tween-20 
 
Mowiol 
6g Glycerol 
2.4g Mowiol  
6ml H20 
 
TNB 
1g Blocking reagent (supplied by Perkin-Elmer in TSA-Amplification Kit) 
dissolved in 200ml TNT blocking buffer 
 
2.4 Kits and enzymes 
Table 3: Kits and enzymes. 
Kit Company 
BamHI New England Biolabs, UK 
Buffer Revertaid M-MuLV Fermentas, Germany 
DAB Kit Vector Laboratories, Germany 
dNTPs GeneOn, Germany 
EcoRI NEB, UK 
Endo-Free® Plasmid Maxi Kit Qiagen, Germany 
First Strand cDNA synthesis kit Thermo Scientific, Germany 
FuGENE® HD Transfection Reagent Promega, Germany 
NEB Buffer  New England Biolabs, UK 
Oligo(dT)18 Thermo Fisher Scientific, USA 
Pfu DNA Polymerase Promega, Germany 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, USA 
Power SYBR® Green PCR Master Mix Applied Biosystems, USA 
Red Load Taq Master Jena Bioscience, Germany 
Revertaid M-MuLV Reverse Transcriptase Fermentas, Germany 
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Revertaid M-MuLV Buffer Fermentas, Germany 
Riboblock RNase inhibitor Fermentas, Germany 
RNase-free DNase set Qiagen, Germany 
RNeasy® Mini Kit Qiagen, Germany 
Taq Polymerase Genaxxon, Germany 
TSA-Kit Perkin Elmer, USA 
XhoI New England Biolabs, UK 
 
2.5 Antibodies 
Table 4: Primary antibodies against human proteins. 
Antibody Application and 
dilution 
Species Company 
anti – BrdU Alexa Fluor 
555 
IF (1:1,000) mouse Thermo Fisher 
Scientific, USA 
Monoclonal anti-
Androgen Receptor 
AR441 
IF (1:100), WB (1:1,000) mouse Abcam, UK 
Monoclonal anti-
Estrogen Receptor 
alpha Clone 1D5  
IF (1:60), IHC (1:50) mouse Dako, Denmark 
Monoclonal anti-
Estrogen Receptor 
beta ab133467 
IF (1:50), WB (1:1,000), 
IHC (1:900) 
rabbit Abcam, UK 
Monoclonal anti-FLAG 
M2, Clone M2 
WB (1:1,000), IF (1:500) mouse Sigma-Aldrich, 
Germany 
Polyclonal anti-
DYKDDDDK Tag 
Antibody #2368 
IF (1:500), WB (1:1,000) rabbit Cell Signaling, USA 
Polyclonal anti-SMR3A 
ab97942 
IHC (1:25), IF (1:50) rabbit Abcam, UK 
Polyclonal anti-
Cleaved Caspase 3 
(#9661) 
WB (1:1,000), IF (1:400) rabbit Cell Signaling, USA 
Monoclonal anti-beta-
Actin (A2228) 
WB (1:10,000) mouse Sigma-Aldrich, 
Germany 	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Table 5: Secondary antibodies. 
Antibody Application and 
dilution 
Label Company 
goat anti-rabbit IHC (1:200) biotinylated Vector Laboratories, 
USA 
horse anti-mouse  IHC (1:200) biotinylated Vector Laboratories, 
USA 
goat anti-mouse WB (1:5,000) HRP Santa Cruz, 
Germany 
goat anti-rabbit WB (1:5,000) HRP Santa Cruz, 
Germany 
goat anti-rabbit IF (1:200 Cy3 Sigma-Aldrich, 
Germany 
goat anti-mouse IF (1:200) Cy3 Sigma-Aldrich, 
Germany 
 
2.6 Plasmids 
Table 6: Plasmids. 
Plasmid Company 
Myc-DDK-tagged ORF clone of Homo sapiens 
SMR3A (NM_12390) 
Origene, USA 
pcDNA 3.1 Invitrogen, USA 
pcDNA 3.1 - eGFP Invitrogen, USA 
 
2.7 Activators and Inhibitors 
Table 7: Activators and inhibitors used for cell-based studies. 
Compound Company 
17-beta-estradiol Sigma-Aldrich, Germany 
4-Hydroxytamoxifen Sigma-Aldrich, Germany 
Dihydrotestosterone (DHT) Sigma-Aldrich, Germany 
Fulvestrant Sigma-Aldrich, Germany 
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2.8 Cell culture medium and supplements 
Table 8: Cell culture medium and supplements. 
Cell culture medium company 
DMEM without phenol red Thermo Fisher Scientific, USA 
Dulbecco’s modified Eagles Medium (DMEM) PAA, Austria 
Fetal Calf Serum (FCS) Sigma-Aldrich, Germany 
L-Glutamine  Sigma-Aldrich, Austria 
Opti-MEM® I Reduced Serum Medium Gibco, Germany 
Penicillin / Streptomycin Sigma-Aldrich, Austria 
Trypan blue Fluka, Germany 
Trypsin Sigma-Aldrich, Germany 
 
2.9 Cell lines and bacteria 
Table 9: Human carcinoma cell lines and bacterial strains. 
Name Type Source 
Cal-27 human oral adenosquamous 
cell carcinoma 
ATCC, USA 
Detroit562 human pharyngeal squamous 
cell carcinoma 
ATCC, USA 
E.coli JM109 commercial competent bacteria Stratagene, La Jolla, USA 
FaDu human pharyngeal squamous 
cell carcinoma 
ATCC, USA 
HeLa human adenocarcinoma of the 
cervix 
 
ATCC, USA 
MCF-7 human adenocarcinoma of the 
mammary gland 
ATCC, USA 
SCC-25 human squamous cell 
carcinoma of the tongue 
ATCC, USA 
THP-1 human monocytic cell line from 
an acute monocytic leukemia 
patient 
ATCC, USA 
UMSCC-17b human squamous cell 
carcinoma of the supraglottis 
kindly provided by Dr I. Tinhofer 
(Charité Universitätsmedizin 
Berlin, Germany) 
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2.10 Primers 
All used primers were designed using Primer Blast Tool (NCBI) and targeted against 
human proteins. 
 
Table 10: Primers. 
Gene  Direction (5’ – 3’) Sequence Tm 
SMR3A forward CTCCTCCACCATGTTTTC 57.9°C 
reverse GAGTGTGATTGAATTCTC 49.2°C 
Estrogen receptor 
beta (ESR2) 
forward AAGAGCTGCCAGGCCTGCCG 75°C 
reverse GCCCAGCTGATCATGTGAACCA 71.6°C 
Estrogen receptor 
alpha (ESR1) 
forward CAAGCCCGCTCATGATCAA 67.4°C 
reverse CTGATCATGGAGGGTCAAATCCAC 69.5°C 
Androgen receptor 
(AR) 
forward AAGACGCTTCTACCAGCTCACCAA 68.9°C 
reverse TCCCAGAAAGGATCTTGGGCACTT 71.4°C 
LaminB1 (LMNB1) forward GCTGCTCCTCAACTATGCTAAGAA 64.6°C 
reverse TTTGACGCCCAGAATCCAC 66.1°C 
 
2.11 Software 
Table 11: Software. 
Software Supplier 
Hamamatsu NanoZoomer Hamamatsu, Germany 
IBM SPSS Statistics IBM Corporation, USA 
ImageJ W. Rasband, USA 
Microsoft Office 2010 Microsoft, USA 
Papers 2 Mekentosj, Netherlands 
PrimerBlast NCBI, USA 
StepOne™ Software Life Technologies, Germany 
TScratch Software Tobias Gebäck and Martin Schulz, ETH Zürich 
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3 Methods 
3.1 Cell Biology 
3.1.1 Splitting and cultivation of cells 
Cells were split when culture had reached approximately 80% confluency. After 
washing cells twice with pre-warmed PBS, 1ml of Trypsin was added and culture was 
incubated for 5 minutes to detach the adherent cells from flask or dish. The reaction 
was stopped using serum-containing medium with all supplements, and the 
suspension was centrifuged for 3 minutes at 1,000 rpm. After re-suspending the 
pellet in DMEM with serum and supplements, cells were counted using trypan-blue 
and the appropriate amount of cells was seeded into a new flask, petri dish or well 
plate containing medium with serum as well as supplements. 
 
The cells were cultivated in a humidified atmosphere of 6% CO2 and 37°C. Media 
exchange took place 24 hours after splitting to remove all remaining Trypsin. 
 
3.1.2 Thawing and seeding of cells 
For freezing, cells were cultured in T75 flasks till 90% confluency was reached. After 
removal of medium, cells were washed two times with pre-warmed PBS before 
addition of 1ml of Trypsin to detach the adherent cells. After incubation for 5 minutes 
within the cell incubator, the reaction was stopped using DMEM medium containing 
serum and supplements. The suspension was centrifuged for 3 minutes at 1,000 rpm 
before re-suspending the pellet in new medium containing serum and supplements. 
Cells were counted and 1,000,000 cells were centrifuged again. The pellet was re-
suspended in freezing medium (60% DMEM, 20% DMSO, 20% FCS) and the cell 
suspension was transferred into cryo-vials. Those were put into a freezing box to 
allow constant freezing of 1°C per minute. Finally, the vials were stored at -80°C or 
into liquid nitrogen. 
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For thawing, the cryo-vials were withdrawn from -80°C and shortly put into the water 
bath to allow de-freezing. The cell suspension was transferred into a T25 or T75 flask 
containing the appropriate amount of medium with serum as well as supplements. 
Medium was exchanged after 24 hours to remove the remaining DMSO from the 
medium. 
 
3.1.3 Treatment of cells 
The cells were treated with different substances. For all experiments in which cells 
were treated with estradiol alone or in combination, serum-free and phenol-red-free 
medium was used to avoid side effects based on the serum as well as on the 
estradiol-like structure of phenol red. Details and concentrations for cell treatment are 
summarized in table 12. 
 
Table 12: Substances and concentrations used for cell treatment. 
Substance Final concentration Time of treatment Medium 
17-beta-estradiol (E2) 1.5nM – 15µM 2 hours for transcript 
detection 
16 hours for protein 
detection 
serum – free / 
phenol-red-free 
medium 
4- Hydroxytamoxifen 
(TAM) 
1µM 2 hours for transcript 
detection 
16 hours for protein 
detection 
serum – free / 
phenol-red free 
medium 
Dihydrotestosterone 
(DHT) 
1µM 2 hours for transcript 
detection 
serum – free/ 
phenol-red free 
medium 
Fulvestrant 5nM – 10nM 24 hours or 48 hours for 
protein detection 
serum – free / 
phenol-red free 
medium or normal 
medium 
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3.1.4 Transient transfection and single cell clones 
200,000 cells were seeded into 6-well plates 24 hours before transfection. 
Transfection was carried out using FuGENE® HD Tranfection Reagent following 
manufacturers’ instructions. 3µl of FuGENE® HD Transfection Reagent was mixed 
with 46µl Opti-MEM® I reduced Serum Media and incubated for 5 minutes at room 
temperature. Afterwards, 1µg of SMR3A-overexpression plasmid (Myc-DDK-tagged 
ORF clone of Homo sapiens SMR3A) or mock control plasmid (pcDNA 3.1) was 
added and incubated one more time for 15 minutes before adding the solution drop-
wise to the cells. 24 hours after transfection, medium was exchanged to G418-
medium for selection. In the aim to determine the endpoint of selection, an eGFP-
containing construct without antibiotics resistance was used as internal control. 
 
To achieve single cell clones, after the end point of selection pressure, cells were 
titrated into 96-well plates to achieve finally one single clone per well. Single clones 
were transferred into 24-well plates and screened using immunofluoresence for 
SMR3A overexpression. Positive clones were expanded and used for future assays.  
 
3.1.5 Proliferation assay 
Proliferation rate was determined using a BrdU-incorporation assay. 30,000 cells 
were seeded into 12-well plates on 18mm coverslips. 14 hours after treatment with 
estradiol and / or 4-Hydroxytamoxifen as well as control treatment, BrdU pulse 
labeling was performed. 1mM BrdU-solution in PBS was added to serum-containing 
medium for 2 hours. Afterwards, medium was removed and cells were washed twice 
with PBS before fixation using ice-cold methanol for 7 minutes. Cells were again 
washed with PBS before incubating with 2N HCl solution for 30 minutes at 37°C. 
Next, Borate buffer (0.1M) was added for 10 minutes at room temperature and cells 
were washed with PBS. Afterwards, the cells were blocked with 10% goat-serum in 
0.1% Triton X-100 in PBS before adding the primary antibody (anti-BrdU-antibody) 
overnight at 4°C. Finally, after washing, cells were counterstained with H33324 for 5 
minutes to stain the nuclei. Cells were again washed using PBS and finally the 
coverslips were embedded with Mowiol prior to microscopy.  
Material and Methods 
	   25	  
For analysis, the ratio of BrdU-positive cells vs. the total number of cells (H33324 
positive cells) was determined for ten randomly selected areas. Mean value + SEM 
were plotted per condition. 
 
3.1.6 Migration assay 
For the migration assay, IBIDI culture inserts were used within a 6cm dish. 300,000 
cells were seeded into each chamber of the insert in a total volume of 70µl. After 8 
hours, the IBIDI insert was removed and the 6cm dish was carefully covered with 
medium to avoid detachment of the cell layer. Gap closure was imaged every two 
hours until the gap was completely closed. The migratory capacity was analyzed 
using freely available TScratch software. % of gap closure + SEM was plotted for 
each individual time point measured in triplicates. 
 
3.1.7 Adhesion assay 
To determine the adhesive capacity of cells, 10,000 cells were seeded into 12-well 
plates. To defined time points of 30 minutes to 4 hours, non-adherent cells were 
washed away using PBS. Adhesive cells were fixed using ice-cold methanol for 7 
minutes on ice. Methanol was removed and crystal violet solution was added to the 
cells for a few minutes. Unbound dye was removed by intensive washing with tap 
water. Adherent cells were determined as relative covered area using ImageJ 
software and plottet + SEM for every time point measured in triplicates. 
 
3.2 Biochemistry 
3.2.1 Whole cell lysate preparation and protein concentration measurement 
To prepare whole cell lysates, medium was removed and cells were washed twice 
using ice-cold PBS. Afterwards, 1ml of ice-cold PBS was added to the dish and cells 
were scraped and transferred into an Eppendorf tube. The suspension was 
centrifuged for 5 minutes at 3,000 rpm at 4°C. The pellet was re-suspended into the 
double amount of RIPA-buffer containing protease as well as phosphatase inhibitors. 
The suspension was mixed and incubated on ice for 15 minutes. After centrifugation 
for 10 minutes at 13,000 rpm at 4°C, the supernatant, which contains all proteins, 
was transferred into a new Eppendorf tube. 
Material and Methods 
	   26	  
 
Protein concentration was measured using the BCA-method. In brief, BCA Reagent 
A and B were mixed in a ratio of 1:50. 10µl of pre-diluted probe (1:10), standard or 
blank were mixed with 200µl of BCA Reagent mixture in a 96-well plate and 
incubated for 30 minutes at 37°C in the dark under permanent shaking. Afterwards, 
the absorption at 562nm was measured and the protein concentration was calculated 
manually. 
 
3.2.2 Western Blot 
Equal amounts of whole cell lysates were mixed with 4x Laemmli buffer and heated 
for 5 minutes at 95°C. 20µg of protein was loaded on a 10% - 12% SDS-PAGE 
depending on the size of the protein which should be determined. The gel 
composition is listed in table 13.  
The gel run was performed in a running chamber using 1 x running buffer. As a 
marker, the Precision Plus Protein™ Standard was used to determine protein size. 
After the gel run, the probes were transferred from the gel onto a PVDF membrane 
using a MiniProtean Wet Blot Chamber using the Wet Blot method according to the 
manufacturer instructions. In brief, filter papers and the PVDF membrane, which was 
pre-activated using methanol for 10 seconds, were cut to fit onto the gel. The 
sponges and filter papers were soaked with transfer buffer and build up according to 
the instruction of the manufacturer. The transfer lasted 1 h in transfer buffer at 100 V 
under permanent cooling using ice blocks. 
 
Afterwards the immunodetection of the proteins was performed on the membrane. 
After blocking the membrane either with 5% milk or BSA in PBST, the primary 
antibody was added and incubated for at least 1 hour at room temperature or 
preferentially overnight at 4°C. After washing the membrane for three time with 
PBST, the incubation with the according secondary antibody coupled with 
horseradish peroxidase (HRP) was performed for 1 hour at room temperature diluted 
in 5% milk or BSA in PBST. Finally, the blot was again washed with PBST as well as 
PBS and developed with the ECL reagent for the appropriate time using the Image 
Quant LAS 500 gel imaging system.  
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Table 13: Composition of resolving and stacking gel. 
 for 10% resolving gel for 12% resolving gel for stacking gel 
0.5M Tris pH 6,8   1.25ml 
1.5M Tris pH 8,8 2.5ml 2.5ml  
40% Acrylamid/ Bis 2.5ml 3ml 0.5ml 
10% SDS 100µl 100µl 50µl 
H2O 4.85ml 4.35ml 3.2ml 
APS 50µl 50µl 25µl 
TEMED 5µl 5µl 5µl 
 
3.3.3 Immunofluorescence (IF) 
For immunofluorescence, 30,000 cells were seeded in 12-well plates with 18mm 
coverslips. Cells were treated according to the individual experimental setup. 
Afterwards, cells were fixed using 4% Formalin in PBS for 30 minutes at room 
temperature. After intensive washing with PBS, cells were permeabilized using X-
Buffer for 30 minutes. Next, cells were again washed three times with PBS and 
blocked using T-Buffer for additional 30 minutes at room temperature before 
incubation with the primary antibody diluted in T-Buffer for 1 hour at room 
temperature or over night at 4°C. The cells were again washed three times using 
PBS and the secondary antibody plus H33324 to counterstain the nucleus were 
added for 1 hour at room temperature diluted in T-Buffer. Finally, cells were again 
washed for two times with PBS as well as once using tap water and embedded with 
Mowiol. Immunofluorescence pictures were taken in the appropriate channel 
including the visualization of the nuclei using H33324 to identify the localization of the 
protein. 
 
3.3.4 Immunohistochemistry (IHC) 
For immunohistochemistry (IHC), paraffin-embedded sections were used. First, 
samples were deparaffinised using two times Xylol for 5 minutes and afterwards 
hydrated using ethanol in dropping concentrations each time for 3 minutes (100%, 
100%, 90%, 70%). To block endogenous peroxidase, samples were incubated with 
3% H2O2 solution diluted in 70% ethanol for 10 minutes within the dark. For antigen 
retrieval, slides were steamed in a bath containing sodium citrate buffer (pH 6.0) for 
30 minutes. After cooling down for 40 minutes, the slides were put into PBS and 
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encircled using a hydrophobic PAP pen. Slides were washed in TNT buffer before 
blocking with TNB for 30 minutes at room temperature in a wet chamber to prevent 
the tissue sections from drying out. Afterwards, slides were incubated with the 
primary antibody diluted in TNB either for 1 hour at room temperature or overnight at 
4°C. Sections were again washed using TNT three times before adding secondary 
antibody diluted in TNB for 1 hour at room temperature. Afterwards, signal 
amplification was performed using a TSA Signal Amplification Kit. Therefore, 
Streptavidin solution (1:100 diluted in TNB) was added first for 30 minutes, followed 
by Tyramid (1:200 diluted in Amplification Reagent; provided within the TSA 
Amplification Kit by Perkin-Elmer) for exactly 10 minutes and finally again 
Streptavidin (1:100 diluted in TNB) for additonal 30 minutes. Between each step, 
three washing steps were performed using TNT buffer. The signal was developed 
using the DAB kit according to instructor’s manual. Finally slides were counterstained 
using haematoxylin solution for a few minutes and washed using tapped water for 10 
minutes. Slides were embedded using Eukitt and investigated using light microscopy.  
 
3.4 Molecular Biology 
3.4.1 RNA preparation and quantification 
200,000 cells were seeded in 6-well plates. After treatment conditions, cells were 
washed three times with PBS and 700µl of RLT buffer, supplied within the RNeasy® 
Mini Kit, was added to the plate. Cells were lysed using a cell scraper and transferred 
into an Eppendorf tube. The RNA was isolated using the RNeasy® Mini Kit according 
to the manufacturers’ procedure including the DNase digestion step. RNA was eluted 
in a final volume of 30µl and quantified using NanoDrop technology. 
 
3.4.2 cDNA synthesis 
For cDNA synthesis, 1µg of RNA was transcribed into cDNA using the First strand 
cDNA synthesis Kit according to the instruction of the manufacturer. CDNA quality of 
was tested using a semi-quantitative PCR against human LaminB1 (LMNB1).  
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3.4.3 Semi-quantitative PCR and gel electrophoresis 
For semi-quantitative PCR, the Red-Load Taq Master was used. The following 
Master Mix (table 14) was used for each individual PCR. 
 
Table 14: Master Mix for semi-quantitative PCR. 
Compound Volume (in µl) Final concentration 
Red Load Taq Master 4 1x 
Primer Forward 2 1µM 
Primer Reverse 2 1µM 
RNase-free water 11  
cDNA 1 1ng/µl 
 
The PCR run was adapted to the individual melting temperatures (Tm) of the primers 
used. The following protocol (table 15) was used for the run.  
 
Table 15: PCR run protocol. 
Temperature Time Cycles 
95°C 5:00 1 
95°C 0:20 
35 Tm – 3°C 0:35 
72°C 0:45 
72°C 5:00 1 
4°C forever 1 
 
After the run, the PCR product was loaded on a 2% agarose gel labelled with Gel-
Red (1:10,000) for visualization of the PCR product. The gel was running using 1 x 
TBE buffer and finally imaged using the Image Quant LAS 500 gel imaging system.  
 
3.4.4 RQ-PCR 
For RQ-PCR, the StepOne Plus™ Real-Time PCR system from Applied Biosystems 
was used. CDNA probes as well as standard curve probes were added as triplicates 
into the plates. The standard curve probes were used to determine the primer 
efficiency in parallel to the run. Finally, a water control was added in triplicates to 
determine the background signal. 
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The cDNA probes were diluted 1:10 for hLaminB1 RQ-PCR and were not diluted for 
SMR3A RQ-PCR. Table 16 shows the used Master mix. 
As read-out signal, Power SYBR® Green was used and results were analyzed using 
the ΔΔCt method. The gene of interest (GOI) was standardized to the house-keeping 
gene (HKG) using the median value of triplicates.  
 
Table 16: Master Mix for RQ-PCR using StepOne™ Plus Real-Time PCR system. 
Compund stock solution final concentration 
Power SYBR® Green 2x 1x 
Primer forward 10µM 62.5nM 
Primer reverse 10µM 62.5nM 
water  up to 20µl 
cDNA 20ng/µl diluted 0.5ng/µl 
undiluted 5ng/µl 
 
3.4.5 Bacterial Transformation 
For amplification of commercially available plasmids, bacterial transformation and 
plasmid isolation were performed. One aliquot (100µl) of competent E.coli JM109 
was thawed on ice for 10 minutes before adding 1µg of plasmid in order to amplify 
the plasmid. The mixture was incubated for 30 minutes on ice before performing heat 
shock for 45 seconds at 42°C using a heating block. Cells were cooled down on ice 
for additional 2 minutes and 900µl of LB medium was added and incubated for 30 
minutes at 37°C to allow the bacteria to grow as starting culture. 200ml of LB medium 
was added to an Erlenmeyer and the antibiotic was added according to the 
resistance of the plasmid. 250µl of starting culture was added to the Erlenmeyer and 
incubated overnight at 37°C shaking. The incubation was stopped the next morning 
in case the solution was turbid. Erlenmeyer was removed from 37°C and cooled 
down for 2 hours at 4°C before performing plasmid isolation. 
 
3.4.6 Plasmid isolation and measurement 
For plasmid isolation, the Endo-free® plasmid kit was used according to 
manufacturer’ instructions. Depending on pellet size after column purification, RNase 
free water was added and the DNA content was measured using NanoDrop 
technology. DNA was mixed with its 2.5-fold volume with a mix of 100% ethanol and 
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10% 3M sodium acetate and incubated for 30 minutes at -20°C before centrifugation 
at 7,000 rpm for 15 minutes at room temperature. Supernatant was removed and the 
pellet was dried. RNase-free water was added to finally achieve a solution of 1µg/µl. 
Concentration was checked using NanoDrop spectrophotometer.  
 
3.4.7 Restriction enzyme digestion 
Restriction enzyme digest was performed to check the plasmid after purification. 
Single- and double-digests were done in parallel. 1µg of purified plasmid as well as of 
a control plasmid were digested. Double digest enzymes were analyzed using freely 
available Double-Digest-Finder from New England Biolabs. 
Digest was performed for 1 hour at 37°C. Reaction was mixed with DNA loading 
buffer and run on a 2% agarose gel for gel electrophoresis and monitored using 
Image Quant LAS 500 gel imaging system. 
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4.1 SMR3A expression in HNSCC cell lines and establishment of 
FaDu clones with ectopic overexpression 
An HNSCC cell line with ectopic SMR3A overexpression should be generated as a 
cell culture model to address its impact on tumor-relevant processes. Basal SMR3A 
transcription was monitored in several well-established HNSCC cell lines using RQ-
PCR analysis. SMR3A transcription was hardly detectable in FaDu, SCC25 and 
UMSCC-17b cells, while low basal expression was evident in Cal27 and Detroit562 
cells (Fig. 5). It is worth noting that the Ct values for the SMR3A amplicon with 
undiluted cDNA was in the range between 27 and 30, indicating a rather low basal 
transcription even for Cal27 and Detroit562 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Quantification of basal SMR3A transcript levels in HNSCC cell lines. 
CDNA from HNSCC cell lines was analyzed by RQ-PCR using the ΔΔCt method. Amplification of 
LMNB1 served as internal control and values for FaDu cells were set to one. Bars represent relative 
SMR3A transcript levels as mean values + SEM of three independent experiments measured in 
triplicates. 
 
FaDu cells with the lowest basal transcript level were selected to generate a cell 
culture model with ectopic SMR3A overexpression. First, FaDu cells were transfected 
with either pCMV6-SMR3A-Myc/DDK (FaDu-SMR3A) or a control plasmid (FaDu-
Mock). Following selection with G418 for one week, single clones were generated by 
titration as described in more details in Material and Methods.  
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Ectopic SMR3A overexpression was demonstrated on transcript level by RQ-PCR 
analysis (Fig. 6), and was further confirmed on protein level by immunofluorescence 
staining (Fig. 7 and 8) as well as using Western blot analysis (Fig. 9). Two clones 
with ectopic SMR3A overexpression (FaDu-SMR3A #1 and #2) and two mock control 
clones (FaDu-Mock #1 and #2) were selected for further analysis. The Ct-values of 
the FaDu – Mock clones were comparable to basal SMR3A expression of FaDu cells 
as measured above. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Confirmation of ectopic SMR3A-overexpression in FaDu-SMR3A clones by RQ-PCR. 
CDNA from FaDu-SMR3A and FaDu-Mock clones were analyzed by RQ-PCR using the ΔΔCt method 
and amplification of LMNB1 served as internal standard for normalization. Bars represent mean values 
+ SEM of one experiment measured in triplicates. 
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Figure 7: Confirmation of ectopic overexpression in FaDu-SMR3A clones by IF staining. 
Representative pictures of an immunofluorescence staining demonstrate ectopic SMR3A expression 
(red signal) in FaDu-SMR3A clones, but not in FaDu-Mock controls. Nuclear staining was done using 
H33324 (blue signal). Scale bar represents 20µm.  
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Figure 8: Immunofluorescence analysis of FaDu single cell clones using anti-MYC-Tag 
antibody. 
Representative pictures of an IF staining demonstrating the expression of the SMR3A-MYC-tag fusion 
protein (red signal) in FaDu-SMR3A clones but not in FaDu-Mock clones. Nuclear staining was 
performed using H33324 (blue signal). Scale bar represents 40µm. 
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Figure 9: Detection of the SMR3A-MYC/DDK fusion protein by Western Blot analysis. 
Whole-cell lysate from FaDu-SMR3A clones and mock controls were separated by a SDS-PAGE, and 
expression of the SMR3A-MYC/DDK fusion protein was determined by Western blot analysis using an 
anti-MYC-Tag antibody. Detection of β-Actin served as a control for quantity and quality of protein 
lysates. 
 
In summary, presented data confirmed the successful establishment of FaDu clones 
with stable overexpression of SMR3A on trancript as well as on protein levels for 
further functional studies. 
 
4.2 SMR3A overexpression has no impact on proliferation, 
migration or adhesion of FaDu cells 
First, the consequence of elevated SMR3A expression on cell proliferation was 
assessed in a BrdU incorporation assay. Clones were seeded on coverslips, cultured 
for 24 hours and a pulse labeling with BrdU was performed for two hours. Following 
immunofluorescence staining with an anti-BrdU antibody, ten representative pictures 
were taken to determine the percentage of BrdU-positive cells (Fig. 10). However, no 
significant difference (p= 0.167) was found between FaDu-SMR3A clones and mock 
controls.  
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Figure 10: Proliferation capacity of FaDu-SMR3A and FaDu-Mock clones as determined by a 
BrdU incorporation assay. 
FaDu-Mock and FaDu-SMR3A clones were seeded on coverslips and BrdU pulse labeling was 
performed for two hours. Cells were stained via immunofluorescence with an anti-BrdU antibody. Ten 
representative pictures were taken (A) and ratio of BrdU-positive cells vs. total number of cells 
depicted by H33324 staining was calculated (B). Both individual clones were summarized. Bars 
represent mean values + SEM of three individual experiments. Scale bar represents 20µm. 
 
Next, the impact of ectopic SMR3A expression on cell migration was investigated in 
an ibidi chamber assay. FaDu-SMR3A clones and mock control cells were seeded 
into an ibidi chamber and images were taken every second hour to monitor the 
kinetic of gap closure. Again, no significant difference was found between FaDu-
SMR3A clones and mock controls (Fig. 11). 
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Figure 11: Migration capacity of FaDu-SMR3A clones and mock controls in an ibidi chamber 
assay. 
FaDu-SMR3A clones and FaDu - Mock control cells were seeded into ibidi migration chambers. 
Migration was monitored as percentage of gap closure for each clone. Both clones were summarized 
in one bar. Bars show mean values + SEM of three independent experiments measured in triplicates. 
Analysis was done using TScratch Software. 
 
Finally, FaDu-SMR3A clones and mock control cells were seeded and the kinetic of 
cell adhesion was assessed via crystal violet staining at distinct time points.  
Again, ectopic SMR3A overexpression had no significant impact on adhesive 
capacity (Fig. 12). 
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Figure 12: Adhesion of FaDu-SMR3A clones and mock control cells. 
FaDu-SMR3A clones and mock control cells were seeded into 12-well plates. The amount of adhesive 
cells was monitored by crystal violet staining for the individual clones, which were summarized in one 
bar depicting the covered area of adherent cells. Bars represent mean values + SEM of three 
independent experiments measured in triplicates.  
 
In summary, ectopic SMR3A overexpression had no major impact on tumor cell 
proliferation, migration as well as adhesion, questioning a causal link between 
SMR3A expression and tumor relevant features.  
 
However, these findings raised another important question, whether SMR3A serves 
as a molecular biomarker for a distinct subpopulation of tumor cells, which are 
characterized by resistance to established treatment modalities and consequently 
represent a major source for tumor relapse. 
 
4.3 Accumulation of SMR3A- positive tumor cells upon fractionated 
radiation. 
So far the presented data raised the attractive question whether tumor relapse 
originates from SMR3A-positive tumor cells due to an intrinsic or acquired resistance 
of these cells to established treatment modalities. This might explain the poor clinical 
outcome of the subgroup of OPSCC patients with a high SMR3A staining pattern in 
the previous study (53). It is worth noting that current treatment options for patients 
with an advanced HNSCC include definitive or adjuvant radiotherapy (4,54).  
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As clonal evolution and repopulation of radioresistant tumor cells is likely a major 
cause for tumor relapse, SMR3A expression was investigated in FaDu and Cal27 
cells upon fractionated irradiation with the clinically relevant dose of 2 Gy (Fig. 13).  
 
 
Figure 13: Schematic presentation of the fractionated irradiation protocol. 
30,000 cells were seeded on day 1. Cells were irradiated on four consecutive days (day 2 to day 5) 
with a daily dose of 2 Gy. On day 6, cells were fixed and prepared for IF analysis. 
 
IF staining revealed in all FaDu cells that were alive upon application of the 
fractionated irradiation protocol a strong induction of SMR3A as compared to 
untreated controls (Fig. 14, upper panel). Similar data were obtained for Cal27 cells 
(Fig. 14, lower panel). 
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Figure 14: SMR3A protein expression in FaDu and Cal27 cells after fractionated irradiation. 
Representative pictures of an IF staining to detect SMR3A protein levels (red signal) in FaDu or Cal27 
cells with or without fractionated irradiation (FR) with a daily dose of 2 Gy. Staining of the nuclei was 
done using H33324 (blue signal). Bar represents 20µm. 
 
These data suggest an accumulation of radioresistant cells under fractionated 
irradiation, which are characterized by increased SMR3A expression. The 
mechanism for SMR3A upregulation upon radiation still needs to be elucidated. 
 
4.4 SMR3A expression in salivary glands 
Checking the basal expression of SMR3A in healthy as well as tumor tissue using the 
HumanProtein Atlas (www.proteinatlas.org), we found that the salivary gland is the 
only tissue basally expressing high levels of SMR3A. No other gland, neither 
exocrine like the pancreas or the mammary gland nor endocrine like thyroid or 
adrenal glands is known to express SMR3A (www.proteinatlas.org). 
 
To prove the findings of basal SMR3A protein expression in salivary glands, tissue 
section of the parotis, the major salivary gland in humans was stained. As expected, 
a high SMR3A expression was detected using IHC staining within the cytoplasm 
(Fig. 15). 
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Figure 15: SMR3A protein expression within the human parotis. 
Representative picture of an IHC staining of a human parotis tissue section. The tissue was stained for 
SMR3A protein expression with an antibody against human SMR3A (brown signal). Counterstaining of 
the tissue was done using haematoxylin solution (blue signal). 
 
4.5 Expression of androgen and estrogen receptors in HNSCC cell 
lines 
SMR3A is the abbreviation for submaxillary gland androgen regulated protein 3A and 
belongs to the family of opiorphins. As shown above, the only tissue specimens 
expressing SMR3A are salivary glands. The development of salivary glands is mainly 
mediated by hormonal receptors, e.g. the androgen receptor (AR) and both isoforms 
of the estrogen receptor, estrogen receptor alpha (ESR1) as well as estrogen 
receptor beta (ESR2) (55-57), suggesting a potential link between androgen or 
estrogen-related signaling and SMR3A expression.	  
In order to prove this hypothesis, expression of AR, ESR1 and ESR2 was 
investigated in head and neck squamous cell carcinoma cell lines. First, the 
expression of AR was assessed by semi-quantitative RT-PCR with cDNA from FaDu 
and Cal27 cells as well as THP-1 cells, a human monocytic cell line derived from an 
acute monocytic leukemia patient known to express high levels of AR (58). 
As expected, a prominent AR expression was easily detectable in THP-1 cells, while 
no transcripts were found in any of the HNSCC cell lines tested (Fig. 16) excluding a 
regulation of SMR3A via the androgen receptor in our HNSCC cells. 
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Figure 16: Basal expression of the androgen receptor in HNSCC cells. 
Androgen receptor (AR) transcript levels were analyzed by semi-quantitative RT-PCR with cDNA from 
two HNSCC cell lines (FaDu and Cal27) and THP-1 cells as positive control. Amplification of LMNB1 
served as control for the cDNA quality and quantity. 
 
Next, basal expression of estrogen receptor alpha (ESR1) and estrogen receptor 
beta (ESR2) was determined by semi-quantitative RT-PCR with cDNA of FaDu and 
Cal27 cells. No ESR1 transcript was found in any of the two HNSCC cell lines (Fig. 
17), though ESR1 transcription was evident in MCF-7 cells, a mammary cancer cell 
line, which served as positive control (data not shown). In contrast to ESR1, a 
prominent basal transcription of ESR2 was detected in Cal27 cells but not in FaDu 
cells. 
 
Figure 17: Semi-quantitative PCR to ckeck basal estrogen receptor levels. 
Estrogen receptor alpha (ESR1) and beta (ESR2) transcript levels were analyzed with cDNA of FaDu 
and Cal27. Amplification of LMNB1 served as control for the cDNA quality and quantity.  
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ESR1 and ESR2 expression patterns in FaDu and Cal27 cells were confirmed on 
protein level by Western blot analysis and IF staining (Fig. 18-19). In line with the 
transcript data, no ESR1 protein expression was found in both cell lines, while ESR2 
protein expression was easily detectable in Cal27. It is worth noting that a weak 
signal for ESR2 was found also for FaDu cells by Western blot analysis, which was 
related to the presence of a subpopulation of ESR2-positive FaDu cells as 
determined by IF staining (Fig. 19).  
 
	    
Figure 18: Detection of estrogen receptor proteins in FaDu and Cal27 cells by Western Blot 
analysis. 
Whole-cell lysates from FaDu and Cal27 cells were separated by SDS-PAGE and expression of 
estrogen receptor alpha (ESR1) as well as beta (ESR2) were determined using specific antibodies. 
Detection of β-Actin served as a control for quantity and quality of protein lysates.  
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Figure 19: Immunofluorescence analysis of estrogen receptors in FaDu and Cal27 cells. 
Representative pictures of an IF analysis for estrogen receptor 1 (ESR1) and 2 (ESR2) expression 
(red signal) in FaDu and Cal27 cells. White arrows indicate a subpopulation of ESR2-positive FaDu 
cells. Nuclear staining was done with H33324. Bar represents 20µm. 
 
In summary, these data demonstrated expression of ESR2 but not ESR1 or AR in the 
HNSCC cell lines tested, and suggests a putative regulation of SMR3A expression by 
stimulation via estradiol (E2). 
 
4.6 Estradiol induces tumor relevant processes in HNSCC cell lines 
depending on the estrogen receptor beta. 
So far, our data demonstrate that only estrogen receptor beta is expressed in 
HNSCC cell lines. To test whether the stimulation of ESR2 using a potent ligand 
leads to activation of tumor cells concerning tumor relevant processes, estradiol was 
used as a ligand for ESR2 activation as well as 4-Hydroxytamoxifen as an 
antagonist. 4-Hydroxytamoxifen is the active metabolite of Tamoxifen, the current 
“gold-standard” for estrogen-receptor dependent breast cancer acting as as anti-
estrogen in therapy (59). Furthermore, from literature estradiol is known to have an 
impact on tumor relevant processes such as migration as well as proliferation (60-62). 
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Therefore, the ability of estradiol to activate the proliferative as well as migratory 
capacity of HNSCC cells expressing basal levels of ESR2, namely FaDu as well as 
Cal27 cells, was checked.  
For proliferation studies, FaDu and Cal27 cells were treated with 15µM estrdaiol (E2) 
and 1µM 4-Hydroxytamoxifen (TAM) alone or in combination. After 16 hours, 
differences in cell proliferation were quantified by a BrdU incorporation assay and 
subsequent IF staining. 
Analysis is shown in Figure 20. Treatment with estradiol vs. control treatment led to 
slight increased proliferation, which was not significant. No impact on BrdU ratio was 
determined for 4-Hydroxytamoxifen alone as well as in combination with estradiol. 
 
 
Figure 20: Proliferation of FaDu and Cal27 cells after estradiol and / or 4-Hydroxytamoxifen 
treatment using BrdU incorporation assay. 
FaDu and Cal27 cells were seeded on coverslips, treated for 16 hours and BrdU pulse labeling was 
performed for two hours. Cells were stained via immunofluorescence with an anti-BrdU antibody. Ten 
representative pictures were taken and ratio of BrdU-positive cells vs. total number of cells was 
calculated. Bars represent mean values + SEM of three individual experiments. 
  
We furthermore checked whether estradiol led to increased migratory capacity in ibidi 
chamber assay. Also in this experimental setup, the treatment with estradiol slightly 
increased the migratory capacity but not to a significant degree (data not shown). 
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4.7 Regulation of SMR3A expression by estradiol treatment 
To test whether SMR3A expression is mediated via estradiol, FaDu cells were 
treated with 150nM estradiol (E2) or ethanol as control for up to 4 hours in serum-
free and phenol-red-free medium, and cells were harvested at distinct time points for 
total RNA isolation. Relative SMR3A transcript levels was assessed by RQ-PCR 
analysis and revealed a prominent but transient induction at 120 min upon E2 
stimulation (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Estradiol induced SMR3A transcript levels in a transient manner with a peak at 120 
minutes. 
SMR3A transcript levels were analyzed with cDNA from control (EtOH) and 150nM estradiol (E2) 
treated FaDu cells by RQ-PCR using the ΔΔCt method. Amplification of LMNB1 served as internal 
standard for normalization. Bars represent mean values + SEM of two independent experiments 
measured in triplicates. Statistics were done using unpaired two-tailed t-test; *** p ≤ 0.001. 
 
Next, FaDu cells were treated for 120 minutes with increasing amounts of E2 (1.5nM 
up to 15µM), and RQ-PCR analysis confirmed a concentration dependent induction 
of SMR3A transcript levels (Fig. 22). 
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Figure 22: SMR3A transcript level became induced in a dose-dependent manner. 
 SMR3A transcript levels were analyzed with cDNA from control (EtOH) and 1.5nM - 15µM of estradiol 
(E2) treated FaDu cells by RQ-PCR using the ΔΔCt method. Amplification of LMNB1 served as 
internal standard for normalization. Bars represent mean values + SEM of two independent 
experiments measured in triplicates. Statistics were done using unpaired two-tailed t-test; ** p ≤ 0.01 
*** p ≤ 0.001. 
 
Finally, the kinetic of E2-induced SMR3A expression was assessed on protein level 
using immunofluorescence staining. FaDu cells were treated for 4, 8 and 16 hours 
with either ethanol or 15µM estradiol prior fixation and IF staining (Fig. 23). While no 
specific staining was observed in ethanol-treated controls, a subpopulation of 
SMR3A-positive FaDu cells was detected already at 4 hours upon E2 stimulation. 
There was a further increase in the amount of SMR3A-positive cells after 8 hours and 
16 hours after E2 stimulation, almost all FaDu cells showed a positive staining for 
SMR3A.  
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Figure 23: Estradiol induces SMR3A protein levels in FaDu cells. 
Representative pictures of an IF staining for SMR3A protein levels (red signal) in control (EtOH) and 
15µM estradiol-treated FaDu cells. Nuclear staining was done with H33324 (blue signal). Bar 
represents 20µm. 
 
 
Previous data demonstrated ESR2 expression only in a subpopulation of FaDu cells 
under normal growth conditions (Fig. 19). Accordingly, the prominent induction of 
SMR3A protein via estradiol (Fig. 23) in almost all cells suggested an induction of 
ESR2 expression by E2 treatment.  
 
Indeed, IF analysis revealed a strong induction of ESR2 protein expression 16 hours 
after treatment with 15µM of estradiol (Fig. 24), which was not seen for ESR1 (data 
not shown). 
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Figure 24: Estradiol induces estrogen receptor beta on protein level in FaDu cells. 
Representative pictures of an IF staining for estrogen receptor beta (ESR2) protein levels 16 hours 
upon control (EtOH) or 15µM estradiol (E2) treatment. Nuclear staining was done with H33324. Bar 
represents 20µm. 
 
In summary, these data confirmed an induced expression of SMR3A in FaDu cells by 
estradiol and strongly suggested a critical role of the estrogen receptor beta. 
Consequently, SMR3A could serve as a surrogate marker for active estrogen 
receptor signaling in the pathogenesis and progression of HNSCC.  
 
 
4.8 Estradiol-induced SMR3A expression depends on estrogen 
receptor beta function 
To further confirm that E2 stimulates SMR3A expression in an ESR2 dependent 
manner, FaDu cells were treated with 15µM E2 and 1µM 4-Hydroxytamoxifen (TAM) 
alone or in combination. 4-Hydroxytamoxifen alone had no major impact on basal 
SMR3A transcription, but revealed a strong inhibition of E2-induced transcript levels 
in FaDu cells indicating a pure antagonistic but not agonistic role of 4-
Hydroytamoxifen (Fig. 25). Inhibition of E2-induced SMR3A expression by 4-
Hydroxytamoxifen was also confirmed on protein level by IF staining (Fig. 26). 
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Figure 25: 4-Hydroxytamoxifen inhibits estradiol induced SMR3A transcript levels in FaDu 
cells. 
SMR3A transcript levels were analyzed with cDNA from FaDu cells after treatment with EtOH or 15µM 
estradiol (E2) and 1µM 4-Hydroxytamoxifen (TAM) alone or in combination for 120 minutes by RQ-
PCR using the ΔΔCt method. Amplification of LMNB1 served as internal standard for normalization. 
Bars represent mean values + SEM of two independent experiments measured in triplicates. 
 
 
 
Figure 26: 4-Hydroxytamoxifen inhibits estradiol-induced SMR3A protein levels in FaDu cells. 
Representative pictures of an IF analysis with FaDu cells, which were treated for 16 hours with either 
ethanol (EtOH) or 15µM of estradiol (E2) and 1µM 4-Hydroxytamoxifen (TAM) alone or in combination. 
Cells were stained for SMR3A protein (red signal) expression. Nuclear staining was done using 
H33324. Bar represents 20µm. 
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Results 
	   53	  
 Similar results were obtained for Cal27 cells (Fig. 27), despite higher basal 
expression of SMR3A and ESR2 as shown previously (Fig. 5 and Fig. 18 + 19). 
 
 
Figure 27: 4-Hydroxytamoxifen reduces SMR3A protein levels in Cal27 cells. 
Representative pictures of an IF analysis for SMR3A protein detection (red signal). Cal27 cells were 
treated for 16 hours with either ethanol (EtOH) or 15µM of estradiol (E2) and 1µM 4-Hydroxtamoxifen 
(TAM) alone or in combination. Nuclear staining was done using H33324 (blue signal). Bar represents 
20µm. 
 
Another potent inhibitor of estrogen receptor signaling, which specifically affects 
estrogen receptor beta but not estrogen receptor alpha is Fulvestrant, a novel 
estrogen antagonist. In contrast to the active metabolite of tamoxifen, 4-
Hydroxytamoxifen, which competes with estradiol for the binding to ESR2, 
Fulvestrant can lead to the full degradation of the estrogen receptor (63).  
 
FaDu cells were treated for 24 hours with either DMSO or Fulvestrant at increasing 
doses from 2nM to 10nM. The impact of Fulvestrant treatment on basal ESR2 protein 
levels was assessed by IF staining and revealed a dose-dependent reduction (Fig. 
28).  
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Figure 28: Fulvestrant treatment leads to a dose-dependent reduction of basal estrogen 
receptor beta protein levels in FaDu cells. 
Representative pictures of an IF analysis to detect ESR2 protein levels (red signal) in FaDu cells, 
which were treated with DMSO or increasing doses of Fulvestrant (2-10nM) for 24 hours. Nuclear 
staining was done using H33324. Bar represents 20µM. . 
 
 
In addition to FaDu cells, Fulvestrant did also reduce estrogen receptor beta protein 
levels in Cal27 cells 24 hours after treatment, which was demonstrated by IF staining 
(Fig. 29, middle panel). A complete loss of estrogen receptor beta was observed in 
Cal27 cells 48 hours after treatment with 10nM Fulvestrant (Fig. 29, right panel). 
Differences for the time for complete loss of ESR2 might be explained by higher 
basal receptor expression compared to FaDu cells (Fig. 18). 
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Figure 29: Fulvestrant treatment leads to reduction of basal estrogen receptor beta protein 
levels in FaDu and Cal27 cells. 
Representative picture of an IF staining to detect ESR2 protein levels in FaDu and Cal27 cells, which 
were treated with either DMSO or 10nM of Fulvestrant for 24 or 48 hours. Nuclear staining (blue 
signal) was performed using H33324 staining. Bar represents 20µm. 
 
To address the question, whether Fulvestrant also influences SMR3A protein levels, 
FaDu and Cal27 cells were treated for 24 hours with either DMSO or 10nM 
Fulvestrant. Indeed, IF staining confirmed a complete loss of basal SMR3A protein 
levels in both cells lines (Fig. 30). 
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Figure 30: Fulvestrant inhibits basal SMR3A expression in FaDu and Cal27 cells. 
Representative pictures of an IF staining to detect SMR3A protein levels (red signal) of control 
(DMSO) and 10nM Fulvestrant treated FaDu as well as Cal27 cells. Nuclear staining was performed 
using H33324 (blue signal). Bar represents 20µM. 
 
Next, the impact of Fulvestrant on estrogen receptor beta levels after estradiol 
treatment was assessed. FaDu and Cal27 cells were either treated with DMSO or 
15µM of estradiol in the presence or absence of 10nM Fulvestrant for 24 hours. In 
both cell lines, estradiol increased ESR2 protein levels (Fig. 31 and Fig. 32, E2 
panel), which was inhibited by a combined treatment with Fulvestrant (Fig. 31 and 
Fig. 32).  
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Figure 31: Fulvestrant inhibits estradiol-induced estrogen receptor beta levels in FaDu cells. 
Representative pictures of an IF staining to detect ESR2 protein levels (red signal) of control treated 
FaDu cells or treated with 15µM of estradiol and / or 10nM of Fulvestrant. Nuclear staining was 
performed using H33324 (blue signal). Bar represents 20µm. 
 
 
Figure 32: Fulvestrant inhibits estradiol-induced estrogen receptor beta levels in Cal27 cells. 
Representative pictures of an IF staining to detect ESR2 protein levels (red signal) of control treated 
Cal27 cells or treated with 15µM of estradiol and / or 10nM of Fulvestrant. Nuclear staining was 
performed using H33324 (blue signal). Bar represents 20µm. 
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In order to prove whether Fulvestrant also inhibits hormone-induced SMR3A 
expression, Cal27 cells were treated as described before. SMR3A protein levels 
were determined by immunofluorescence, which confirmed reduced basal and 
estradiol-induced SMR3A expression in the presence of Fulvestrant (Fig. 33). 
 
 
Figure 33: Fulvestrant inhibits estradiol-induced SMR3A levels in Cal27 cells. 
Representative pictures of an IF staining to detect SMR3A protein levels (red signal) of control treated 
Cal27 cells or treated with 15µM of estradiol and / or 10nM of Fulvestrant. Nuclear staining was 
performed using H33324 (blue signal). Bar represents 20µm. 
 
In summary, these data confirmed SMR3A as a downstream target of estradiol in 
HNSCC cells and supported the assumption that its detection serves as a valid 
biomarker not only for estrogen receptor activity but also the efficacy of drugs 
targeting estradiol-dependent signaling. 	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4.9 Accumulation of SMR3A - and ESR2-positive tumor cells upon 
fractionated radiation. 
So far we have shown that SMR3A can be modulated via estrogen receptor beta as 
well as that SMR3A positive tumor cells are enriched in cells with fractionated 
radiation marking cells, which can repopulate upon radiation giving rise to a tumor 
relapse. 
We next investigated whether also estrogen receptor beta is modulated upon 
fractionated radiation. Using the identical experimental setup as shown before (see 
Fig. 13), we stained FaDu as well as Cal27 cells for ESR2-protein with or without 
fractionated irradiation with the clinical relevant dose of 2 Gy (Fig. 34). 
 
IF staining revealed in all FaDu cells that were alive upon application of the 
fractionated irradiation protocol a strong induction of ESR2 protein level, respectively, 
as compared to untreated controls. Similar data were obtained for Cal27 cells (Fig. 
34). 
 
	    
Figure 34: Estrogen receptor beta is increased in HNSCC cells after fractionated irradiation. 
Representative pictures of an IF staining to detect estrogen receptor beta levels (red signal) in FaDu 
or Cal27 cells with or without fractionated irradiation (FR) with a daily dose of 2 Gy. Nuclear staining 
was done using H33324 (blue signal). Bar represents 20µm. 
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These data suggest an accumulation of radioresistant cells under fractionated 
irradiation, which are characterized by elevated estrogen receptor beta signaling and 
consequently increased SMR3A expression. To support this assumption ESR2 and 
SMR3A protein levels were monitored in parallel by IF staining in FaDu cells after 
fractionated irradiation with a dose of 2 Gy for two (2 x 2 Gy) or four days (4 x 2 Gy) 
to determine a possible dose-dependent effect. Prominent staining for both proteins 
was only detected in FaDu cells following the 4 x 2 Gy protocol, and only a slight 
increase was evident following the 2 x 2 Gy protocol (Fig. 35).  
 
 
Figure 35: Estrogen receptor beta and SMR3A become induced in FaDu cells with fractionated 
irradiation in a dose-dependent manner. 
Representative pictures of an IF staining to detect estrogen receptor beta (upper panel; red signal) as 
well as SMR3A protein levels (lower panel; red signal) in FaDu cells with fractionated irradiation for 
two or four times with a single dose of 2 Gy as well as without irradiation. Nuclar staining was done 
using H33324 (blue signal). Bar represents 20µm. 
 
In summary, these data support a critical role of estrogen receptor signaling in 
radioresistance of HNSCC cell lines, raising the attractive question, whether 
pharmacological interference sensitizes these cells to irradiation. To address this 
question, FaDu cells were pre-treated with 4-Hydroxytamoxifen or Fulvestrant and 
subsequently irradiated with the 4 x 2 Gy protocol (Fig. 13). As compared to DMSO-
treated controls, pre-treatment with Fulvestrant revealed accelerated apoptosis upon 
fractionated irradiation as determined by increased levels of cleaved-Caspase 3 in a 
Western blot analysis (Fig. 36). In contrast, pre-treatment with 4-Hydroxytamoxifen 
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alone had no major impact, while slightly increased levels of cleaved-Caspase 3 
were evident in combination with fractionated irradiation. 
  
Figure 36: Accelerated apoptosis of FaDu cells with Fulvestrant in a fractionated irradiation 
protocol. 
Control treated and irradiated (4 x 2 Gy) FaDu cells were co-treated with DMSO, Fulvestrant or 4-
Hydroxytamoxifen (TAM). Protein lysates were prepared and analyzed for cleaved-Caspase 3 levels 
by Western blot to detect apoptosis. Detection of β-Actin served as control for quantity and quality of 
protein lysates. 
 
Increased levels of apoptosis after combined treatment with Fulvestrant and 
irradiation were further confirmed on cellular level by immunofluorescence staining. 
Cells were either control- or Fulvestrant-treated in combination with or without 
irradiation (4 x 2 Gy), and were subsequently stained for protein levels of cleaved-
Casapse 3. In FaDu (Fig. 37) as well as Cal27 cells (Fig. 38), protein levels of 
cleaved-Caspase 3 increased after combined treatment indicating increased 
apoptosis.  
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Figure 37: Levels of cleaved-Caspase 3 become increased upon co-treatment with Fulvestrant 
and irradiation in FaDu cells. 
Representative pictures of an IF staining to detect cleaved-Caspase 3 in FaDu cells with DMSO or 
10nM Fulvestrant treatment with or without irradiation for 24 hours. Nuclear staining was done using 
H33324 (blue signal). Bar represents 20µm. 
 
	    
Figure 38: Levels of cleaved-Caspase 3 become increased upon co-treatement with Fulvestrant 
and irradiation in Cal27 cells. 
Representative pictures of an IF staining to detect cleaved-Caspase 3 in Cal27 cells with DMSO or 
10nM Fulvestrant treatment with or without irradiation for 24 hours. Nuclear staining was done using 
H33324 (blue signal). Bar represents 20µm. 
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4.10 Expression of estrogen receptor alpha and beta in OPSCC 
Next the expression of estrogen receptor alpha and beta was determined on tissue 
section from oropharyngeal squamous cell carcinoma patients (n = 145) by IHC 
staining. Positive staining for ESR2 in tumor cells was observed in 62% of all cases, 
while ESR1 was not detected (data not shown). In line with the results of the cell 
culture experiments, a positive staining for SMR3A and ESR2 on serial sections was 
evident in tumor cells of a substantial amount of OPSCC (Fig. 39, upper panel). 
However, other tumors revealed high ESR2 expression without detectable SMR3A 
co-expression (Fig. 39, lower panel). Later examples might indicate ESR2-positive 
tumor cells in the absence of estradiol-induced signaling. 
 
 
Figure 39: Estrogen receptor beta and SMR3A are co-expressed in tissue samples of HNSCC 
patients. 
Representative pictures of tissue specimen of HNSCC patients parallel stained for ESR2 and SMR3A 
protein expression via immunohistochemistry. 
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In summary, these data indicate a co-regulation of both proteins in established 
HNSCC cell lines as well as tumor tissue. Detection of SMR3A and ESR2 co-
expression in primary tumors specimens or biopsies taken during definitive 
radiotherapy could stratify subgroups of HNSCC patients with a high risk for 
treatment failure. These patients might benefit from adjuvant treatment with 
established drugs such as Tamoxifen or Fulvestrant targeting estrogen receptor beta 
signaling.
Discussion 
	   65	  
 
 
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
	   66	  
 
5.1 Opiorphins in physiology and pathophysiology 
In the past, the murine homologue of SMR3A, Smr1, was identified in an orthotopic 
floor-of-the-mouth mouse tumor model as one of several candidate genes with 
increased expression in recurrent tumors after surgery as compared to their primary 
counterpart (45,46). Prominent SMR3A expression was also found in almost 36% of 
primary tumors in a retrospective study with OPSCC patients, and high protein levels 
were significantly correlated with poor outcome concerning overall- as well as 
progression-free survival (53). These data demonstrated a crucial role of SMR3A-
positive tumor cells in treatment failure of HNSCC patients and suggested a causal 
link between its molecular function and biological traits of tumor cells. 
So far, the physiological and pathological role of SMR3A and other members of the 
opiorphin family have been investigated in the context of erectile dysfunction, sexual 
behavior, analgesic effect as well as depression (48,50-52,64-70).  
Most studies published so far link the role of the opiorphin gene family to erectile 
dysfunction. The pentapeptide of the rat opiorphin Vcsa1, sialorphin, modulates in a 
dose-dependent manner the mating pattern of rats by stimulating their sexual 
motivation (70). Furthermore, sialorphin is known to be downregulated in rats with 
erectile dysfunction. The incorporal injection of the pentapeptide restores erectile 
function (48,69).  
A connection of erectile physiology was also shown for the human homologues 
SMR3A as well as PROL1. Both genes are more than 10-times downregulated in 
men suffering of erectile dysfunction compared to healthy men (52,64). 
Therefore, it is widely accepted that the whole gene family of opiorphins can 
modulate erectile physiology in which they can also be used as a marker gene 
(52,64,70). 
The anti-depressant as well as the analgesic effect of the opiorphins is modulated via 
the µ- as well as the δ-opioid receptors (65,68). Central administration of the opiorphins 
leads to the activation of both receptors leading to increase in mood as well as 
emotional state declaring anti-depressant like effects. Furthermore, the opiorphins 
are declared to have a more potent analgesic effect than the one by morphine. They 
weaken the catabolism of enkephalins, which regulate the pain action within the body 
(65-68). 
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Rosinski-Chupin linked expression of Vcsa1 with androgens. In younger rats, Vcsa1 
is only expressed in a small amount of differentiated acinar cells, which are 
surrounded by an environment of small amounts of androgens within the circulation. 
Acinar cells are mainly found in the salivary glands of the tongue as well the 
mammary glands, the pancreas and the liver. During sexual maturation the level of 
androgen increases in parallel to the amount of cells expressing Vcsa1 (51).     
 
5.2 Overexpression of SMR3A has no major impact on tumor 
relevant processes 
To our knowledge, there are no studies published linking opiorphins to tumor relevant 
processes. In 2013, our group investigated the expression of SMR3A in the context 
of patient outcome concerning overall- as well as progression-free survival. The 
mechanism leading to the poor outcome is still unknown (53). 
Basally none of our cell lines tested expressed large amounts of SMR3A. Most cell 
lines were completely absent of SMR3A expression 
Therefore, single-cell clones of FaDu cells, which lack detectable SMR3A 
expressions under normal growth conditions, with ectopic overexpression were now 
established as a model system to investigate the impact of SMR3A overexpression 
on biological processes in HNSCC cells.  
However, FaDu-SMR3A clones revealed comparable proliferation, migration, 
invasion and adhesion as compared to mock controls. 
 
In a cohort of patients with oropharyngeal squamous cell carcinoma tested only 36% 
of primary tumors displayed a positive SMR3A staining (53). The majority of tumors 
revealed no expression indicating no direct consequence of SMR3A expression on 
neoplastic transformation and initiation of malignant progression. This assumption is 
in line with presented data obtained in the in vitro studies with genetically modified 
tumor cell lines.   
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5.3 SMR3A: a marker for therapy-resistant cells? 
The fact that ectopic SMR3A overexpression was not causally linked with any tumor-
related processes tested, raised the interesting question, whether SMR3A might 
serve as a biomarker for a subpopulation of tumor initiating cells (TICs) with cancer 
stem cell like properties. Characteristic features of TICs are self-renewal as well as 
clonal selection under established treatment modalities and subsequent expansion 
as a driving force for local treatment failure as well as formation of recurrent tumors 
(71-75). As a proof of concept, established tumor cell lines were investigated after 
either a single dose of irradiation as well as fractionated irradiation (4 x 2 Gy). As 
expected, SMR3A was not detectable under basal conditions or single irradiation to a 
high amount, but was significantly induced upon fractionated irradiation. These data 
strongly support a model in which fractionated irradiation results in clonal evolution of 
radioresistant SMR3A-positive tumor cells which could give rise to local recurrences 
as tumor initiating cells (76-79).  
 
To further confirm the clinical relevance of these findings, tumor biopsies should be 
collected and analyzed before adjuvant and during definitive radiotherapy of HNSCC 
patients. The detection of SMR3A-positive tumor cells in primary HNSCC or their 
clonal evolution after several cycles of irradiation could indicate the presence of TICs 
and predict a high risk for treatment failure. Accordingly, detection of SMR3A-positive 
tumor cells might serve as a prognostic biomarker to support treatment decision-
making and to improve appropriate management of HNSCC patients within the 
follow-up period. 
 
5.4 SMR3A is not influenced by androgens 
SMR3A is the abbreviation for submaxillary gland androgen regulated protein 3A. 
The murine opiorphin homologue Smr1 is known to be dependent on androgen, 
which for example triggers its release (48,69). Within the submandibular gland of 
rodents the opiorphins are expressed at high levels. Within the submandibular gland, 
the mRNA of Vcsa1 is significantly increased in male rats in comparison to female 
rats. Furthermore, after castration, androgen levels as well as Vcsa1 levels 
significantly reduced in the submandibular glands and the levels could be induced 
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after androgen therapy in females indicating a direct link between Vcas1 expression 
and the level of androgens within the circulation (51,64).  
Furthermore, genes of the opiorphin gene family are solely expressed within salivary 
glands under physiological conditions. Production of peptides derived from the 
mature proteins by selective cleavage is stimulated by androgens also triggering its 
release into the saliva where they can be quantified using LC-MS/MS (49,80).  
 
Furthermore, the classical risk factors for the development of HNSCC are the high 
consumptions of alcohol as well as tobacco often consumed together having a 
multiplicative effect (4,10,81). Liver dysfunction due to alcohol is often reflected by a 
changed metabolism of sex hormones processing testosterone as well as estrogen). 
Furthermore Marsigliante and coworkers correlated the level of cathepsin D with the 
level of the androgen receptor as well as the estrogen receptor (82). Cathepsin D 
becomes activated within the hepatocytes of the liver where it is responsible for the 
degradation of insulin (83). In 1998, Brysk and coworkers correlated the levels of 
cathepsin D with human oral tumors. They identified the overexpression level as a 
prognostic indicator for the presence of metastasis and furthermore a high level of 
cathepsin D with dedifferentiation of the tumors (84). In 2014, Rades investigated the 
prognostic value of the androgen receptor in advanced HNSCC for metastasis-free 
survival as well overall survival. Using multivariate analysis, they identified the 
androgen receptor as an independent prognostic marker claiming the receptor to be 
considered in future as prognostic value (85). In 2011 Goulioumis and coworkers 
investigated the impact of androgen receptor in laryngeal tumors. Nearly half of the 
tumor specimen expressed the androgen receptor at high levels. Strong expression 
of AR in the nucleus was correlated with features of epithelial to mesenchymal 
transition (EMT) (86), which is known to be involved in unfavorable prognosis of 
HNSCC (4,87) and off interest as a putiative target mechanism for the treatment of 
HNSCC patients (88-90).  
 
All these articles, which are mainly based in patient material and not in cell-based 
systems, claim a connection of androgen receptor to HNSCC mainly concerning 
outcome of patients. 
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Within this study, the androgen receptor was not detectable under normal growth 
conditions in the tested HNSCC cell lines, excluding a direct connection of SMR3A 
expression and the expression of the androgen receptor within the investigated 
context. 
 
5.5 The role of estrogen receptor and androgen receptor in 
physiology and pathophysiology 
There is a close connection between testosterone, dihydrotestosterone (DHT), the 
active metabolite of testosterone, as well as estradiol (Fig. 40) (91,92). 
 
 
 
Figure 40: The hormones estradiol, testosterone and dihydrotestosterone (DHT) are closely 
linked to each other. 
Testosterone can be converted into estradiol as well into dihydrotestosterone (DHT) depending on the 
enzyme. Dihydrotestosterone is the active metabolite of testosterone, being the substrate binding to 
the androgen receptor in most cases. Aromatase converts testosterone into estradiol whereas 
reductase leads to conversion into DHT. 
 
Testesterone 
Estradiol Dihydrotestesterone 
(DHT) 
Aromatase Reductase 
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As depicted in Figure 40, testosterone can be modified into estradiol via the enzyme 
aromatase, but also processed into dihydrotestosterone (DHT) using reductase 
(91,93,94). There is a close connection between the substrates estradiol, testosterone 
as well as DHT and their receptors, the androgen receptors (AR) and the two present 
isoforms of the estrogen receptor (ESR) (95-97). In 2006, Cheng and coworkers 
investigated to presence of the enzyme aromatase in normal keratinocytes as well as 
oral squamous cell carcinomas using primary oral epithelial cell cultures as well as 
tissues. The enzyme was detectable in oral squamous cell carcinomas independent 
of the gender (98).  The concept that aromatase causing locally increased estrogen 
levels has been reported also for breast cancer. In breast cancer, the enzyme is 
locally increased in the adipose tissue surrounding the breast cancer cells (99-102). 
 
5.6 The ESR2-estradiol axis influences tumor relevant processes 
Using estradiol treatment of HNSCC cells (e.g. FaDu as well as Cal27 cells), an 
increased proliferative as well as migratory capacity was observed. These results 
indicate that per se our cells respond to estradiol stimulation inducing tumor relevant 
processes. 
In general many genes, which are regulated upon the estrogen receptor-estradiol-
axis are involved in cell proliferation, inhibition of apoptosis, invasive and migratory 
capacity as well as the promotion of angiogenesis (62,103-105). 
The impacts of the estradiol-ESR2 axis regulating tumor-relevant processes are 
already described in literature. Proliferation for example can be influenced via 
estradiol targeting the estrogen receptor beta in different tumor models such as 
breast cancer, thyroid cancer as well as prostate cancer (62,104,105). In 2009, Egloff 
and coworkers identified the expression of estrogen receptor beta in HNSCC cell 
lines. Stimulation with estradiol induced signal transduction as well as transcriptional 
activity (106). For head and neck cancer, the treatment of premalignant lesion cell 
lines with estradiol resulted in a decreased level of apoptosis, which is also important 
for cancer progression as well as treatment failure. Using tissue samples, the group 
identified an upregulated expression of ESR2 as well as of its ligand estradiol in 
nearly all analyzed tissue samples compared to the normal epithelium (107). 
Furthermore, estradiol stimulation of squamous cell carcinoma tissue as well as cell 
lines significantly increased invasion (108). These date indicate the involvement of the 
E2-ESR2 axis within the carcinogenesis of a diverse range of tumor entities including 
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HNSCC. Furthermore, targeting estradiol-dependent estrogen receptor beta 
activation might be off interest for future therapeutic aspects. 
 
5.7 The role of ESR2 and estradiol in SMR3A regulation 
In a subset of tested HNSCC cell lines no expression of estrogen receptor alpha but 
expression of estrogen receptor beta was evident under normal growth condition or 
upon fractionated irradiation. In addition, an estrogen response element (ERE) was 
found in the proximal promoter of the SMR3A gene. The ERE sequence of the 
SMR3A gene is the preferential binding site for the estrogen receptor to regulate 
gene expression in response to its ligand estradiol (103,109,110). Another possible mode 
of action is “tethering” of other transcription factors by physical interaction with the 
estrogen receptor, which enables regulation of gene transcription in an ERE-
independent manner (109,111,112).  
A significant induction of SMR3A expression on transcript and protein levels upon 
estradiol stimulation of FaDu cells provided experimental evidence for a direct 
involvement of the estradiol – estrogen receptor beta signaling via the ERE within the 
SMR3A promoter in hormone-dependent gene transcription. In the future, the direct 
connection should be investigated using for example reporter gene assays (e.g. 
luciferase assays) or specific mutations in the ERE element to prove the direct 
binding of estradiol to the ERE element of the SMR3A promoter leading to increased 
transcription.  
Using a cohort of oropharyngeal squamous cell carcinomas, we also identified ESR2 
to be expressed not only in cell-based systems but also in tumor specimen of primary 
tumors furthermore confirming a possible role of estrogen receptor beta in HNSCC 
carcinogenesis. 
 
To prove a connection of estradiol- to induce SMR3A upregulation, antagonistic cell 
based assays were performed using selective estrogen receptor modulators 
(SERMs), which are chemically synthesized compounds. Estrogen receptor beta is 
expressed in many tissues within the body. Due to slightly different changes 
depending on the cell within the body where the receptor is expressed, the 
modulation via SERMs is feasible because they vary in their chemical structures 
targeting only in a tissue-dependent context the estrogen receptor (113-115).  
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The estradiol – estrogen receptor beta interaction was first interfered using 4-
hydroxytamoxifen, the active metabolite of tamoxifen. Tamoxifen has agonistic as 
well as antagonistic activities depending on the tissue and can target the estrogen 
receptor alpha as well as estrogen receptor beta (116-118).  
Tamoxifen treatment is declared as the current “gold standard” for treatment of 
estrogen-receptor-positive breast cancer in early as well as advanced stages since 
decades (59,119,120). 
 
In presented experiments, 4-hydroxytamoxifen alone was not able to induce SMR3A 
in FaDu cells, excluding the potential agonistic function in HNSCC cell lines. 
Furthermore, the combined treatment of estradiol and 4-hydroxytamoxifen reduced 
estradiol-induced SMR3A expression to basal levels supporting an antagonistic 
activity of the substance in this experimental setup. These data exclude an impact on 
estrogen receptor alpha, as the receptor was not expressed in any cell lines under 
control conditions or after stimulation.  
 
To further confirm these results Fulvestrant as a potent and more specific antagonist 
of estrogen receptor beta was used. In preclinical mouse models, Fulvestrant 
inhibited the growth of breast cancer cells to a higher content compared to 4-
hydroxytamoxifen as well as of cells which were resistant to 4-hydroxytamoxifen 
(63,121-123).  
 
The compound has the ability to act on the estradiol - estrogen receptor axis in 
different ways as depicted in Figure 41.  
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Figure 41: Fulvestrant can interfere with the estradiol -estrogen receptor beta axis leading to 
downregulation of the receptor. 
Fulvestrant as a classical estrogen receptor beta (ESR2) antagonist can downregulate receptor levels 
on different axis. It can bind with high affinity to ESR2 and prevent binding of estradiol so that 
estradiol-mediated genes cannot be transcribed. Furthermore, Fulvestrant can directly degraded 
ESR2 as well as dissociate the estrogen-receptor-dimers, which are necessary for activation. By 
dissociation the receptor cannot bind to estrogen-response-elements (ERE) to transcribe oestrogen-
sensitive genes.  
(derived from Osborne et al, 2004) 
 
Estrogen receptors need to be present as dimers to be active. Fulvestrant can lead to 
dissociation of the dimer blocking its mode of action and has been shown to induce 
degradation of the receptor. Finally, Fulvestrant can interfere with transcription of the 
estrogen-dependent target genes by stable physical interaction with the estrogen 
receptor beta (63). Similar to 4-hydroxytamoxifen, administration of Fulvestrant 
abrogated estradiol-induced SMR3A expression in FaDu cells, while Fulvestrant 
alone had no effect on its transcript or protein levels. These data did not only support 
a critical role of estradiol – estrogen receptor beta signaling in the regulation of 
SMR3A in putative radioresistant tumor cells but also offered promising drug targets 
for pharmacological interference with tamoxifen or Fulvestrant. Both substances are 
already approved in clinical studies and the therapeutic range as well as the side 
effect profile is well established. Tamoxifen is normally applied orally with a daily 
dose of 20 – 30mg. Fulvestrant, due to its lower bioavailability, is injected monthly via 
intramuscular injection (63,124-126). In future studies concerning the clinical benefit in 
HNSCC, Fulvestrant would be the substance of choice due to a more specific target 
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pattern for estrogen receptor beta, which might cause less side effects such as hot 
flashes, deep vein thrombosis, pulmonary embolism, stroke as well as blood clots 
(59,127-129). Also the treatment with tamoxifen often leads to treatment failure due to 
intrinsic as well as acquired treatment resistance resulting in tumor relapse and 
cancer-related death in nearly 50% of all cases (59,63,116,123,130).  
 
5.8 Role of ESR2 in treatment failure 
The facts that SMR3A expression is induced in almost all tumor cells surviving 
fractionated irradiation and is under the control of estrogen receptor signaling 
strongly suggested a co-regulation of the estrogen receptor beta. Indeed, the 
estrogen receptor beta was co-induced in SMR3A-positive tumor cells after 
fractionated irradiation. In contrast, irradiation with a single dose of 2 Gy was neither 
sufficient to induce SMR3A nor estrogen receptor beta, further supporting the 
assumption that co-induction is a consequence of clonal evolution of radioresistant 
tumor cells. 
A correlation between fractionated irradiation and the upregulation of the estrogen 
receptor is also known from literature (131,132). Torlakovic and coworkers for example 
reported the upregulation of the estrogen receptor beta after irradiation for example 
in a prostatic adenocarcinoma cell line (131).  
 
5.9 SMR3A and estrogen receptor beta: novel biomarkers for 
therapy 
Due to the high risk for treatment failure and unfavorable clinical outcome, there is 
still an urgent need for reliable biomarkers to support treatment decision making for 
patients with advanced HNSCC. In the best case, a distinct biomarker or marker 
panel should discriminate patients, which will benefit from a treatment modality from 
those at a high risk for treatment failure. In this context, detection of SMR3A-positive 
tumor cells in biopsies taken from primary HNSCC at the time of diagnose or from 
non-resectable tumors during definitive radiochemotherapy could indicate the 
presence or accumulation of a subpopulation of radioresistant tumor cells. As 
SMR3A expression is related to ER signaling, these patients might benefit from a 
combined treatment with 4-hydroxytamoxifen or fulvestrant to counteract the clonal 
selection of radioresistant tumor cells, which are the main source for tumor relapse. A 
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positive effect of Fulvestrant on irradiation sensitivity was already shown for breast 
cancer (133). In a combined treatment with Fulvestrant and irradiation as compared to 
irradiation alone, the surviving fraction of tumor cells was significantly reduced 
accompanied by an accelerated cell cycle arrest. Co-treatment with irradiation and 4-
hydroxytamoxifen is also known to improve the local tumor control as well as patient 
survival in breast cancer patients (133). Similar results were also obtained in pilot 
studies with FaDu cells, in which irradiation in combination with Fulvestrant increased 
the level of cleaved-caspase-3 as a marker for apoptosis as compared to single 
treatment with either Fulvestrant or irradiation, respectively.  
 
 
 
Conclusions and future persepctives 
	   77	  
 
 
 
 
Conclusion and future 
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In this study, induced SMR3A and estrogen receptor beta expression were unraveled 
as potential biomarkers for intrinsic or acquired resistance of tumor cells under 
irradiation and as a potential source for tumor relapse in HNSCC patients. Therefore, 
patients co-expressing SMR3A as well as ESR2 to high degree prior to adjuvant 
treatment are of high risk for treatment failure. Those patients might benefit from 
adjuvant therapy in combination with anti-estrogen-receptor-beta-modulators. 
However additional studies are needed to prove the established concept and pave 
the way for clinical trials as well as clinical applications.  
 
In future clinical trials tumor biopsies from head and neck cancer patients could be 
analyzed for the co-expression of SMR3A and ESR2 by immunohistochemical 
staining to evaluate therapeutic efficacy of adjuvant or definitive radiotherapy and to 
predict the risk of a patient for tumor relapse. In case that both proteins are already 
expressed in tumor cells of the primary HNSCC or become up-regulated during 
radiotherapy, an specific targeting of the ESR2-SMR3A axis by estrogen receptor 
beta antagonist, such as 4-hydroxytamoxfen or Fulvestrant, should be tested. 
 
In addition, a better understanding of molecular mechanisms, how estrogen receptor 
signaling enables survival and/or clonal expansion of radioresistant tumor cells is 
urgently needed. 
 In the near future, the interference as well as the therapeutic benefit for HNSCC 
patients has to be elucidated in more detail using different cell line systems. The 
molecular mechanism and involved signaling pathways leading to increased levels of 
apoptosis during combined treatment of radiation and e.g. Fulvestrant have to be 
analyzed in more detail. Furthermore, it might be interesting to know whether HPV, 
which is one of the major risk factors for HNSCC development, has an additional 
impact on the presented treatment regime in the subset of HNSCC patients. To 
answer this question, HPV-positive vs. HPV-negative cell lines should be tested in 
parallel. 
Furthermore, we will perform colony-formation assays (CFA) using Fulvestrant in 
combination with radiation to determine if tumor cells can survive the applied 
treatment. In the ideal case, no colony will survive the combined treatment of 
radiation and e.g. Fulvestrant indicating no cell, which could give rise to recurrent 
tumors preventing a bad outcome for HNSCC patients upon treatment.
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